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Years of dedicated research and billions of dollars of investment made in cancer 
research have significantly increased our understanding of cancer biology. Yet, 
converting this knowledge to more sensitive diagnostics and more effective therapeutics 
is limited by several challenges. For example, in cancer diagnostics, optical-based 
activatable probes such as molecular beacons have been devised to detect protease 
activities of cancer relevant enzymes, but the unwanted degradation of the designed 
linker by non-specific enzymes could result in false signals and thereby limit diagnostic 
accuracy. Additionally, the efficacy of current cancer therapeutics, such as small 
molecule anticancer drugs, are challenged by their hydrophobic nature, as well as their 
non-specific delivery to normal cells which causes side effects as commonly seen in 
cancer chemotherapy. 
The aim of this thesis is to develop a new class of peptide-based supramolecular 
nanostructures with the potential to advance both cancer diagnostics and therapeutics. In 
the first part of this thesis, we designed a series of self-assembling molecular probes with 
an activatable linker embedded within the core of a nanostructure. This particular design 
shields the linker from any non-specific enzymatic degradation prior to reaching the 
targeted site. In the second part, we harnessed the hydrophobic nature of anticancer drugs 
by coupling them to a short peptide with overall hydrophilicity to create self-assembling 
drug conjugates. This conjugation strategy addresses not only the low solubility issue of 
typical hydrophobic drugs, but also the multidrug resistance that cancer cells may have 
developed during the course of chemotherapy. More importantly, these self-assembled 
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nanostructures with diagnostic and therapeutic agents have the potential to increase tumor 
specificity through the enhanced permeability and retention (EPR) effect. 
In the first example, we develop a diagnostic probe system, peptide-based 
molecular beacon, to detect the activities of the target enzyme in cancer cells. A green 
fluorophore reporter was covalently linked to a quencher that effectively reduces the 
reporter’s fluorescence, but could resume its fluorescence upon enzymatic activation. We 
found that the degradable linker is inaccessible to the enzyme in its self-assembled state 
(nanostructure) for protection, but can be activated in its monomeric state to report 
enzymatic activity. Next, we further investigate the effect of shape and charge of self-
assembling molecular beacons in regulating cellular uptake. With the incorporation of a 
β-sheet forming sequence, the beacon molecule can be directed to form both spherical 
and cylindrical nanostructures by controlling self-assembly parameters such as 
temperature and aging time. Furthermore, the surface charges of the nanostructure can be 
altered by customizing the peptide sequences. We found that cancer cells have difficulties 
internalizing negatively charged monomeric molecular beacons as well as extremely 
high-aspect ratio cylindrical nanobeacons. However, cancer cells could rapidly 
internalize positively charged spherical nanobeacons. Following the beacon concept, we 
introduce a fluorescent anticancer drug doxorubicin that gives rise to both therapeutic and 
diagnostic functionalities. This integrated enzymatic-responsive feature enables 
intracellular drug release and fluorescence detection upon linker degradation by the 
specific enzyme. In vitro studies suggest that the drug beacon with a cell penetrating 
peptide can circumvent non-desirable drug resistance response in ovarian cancer cells, 
where higher cell cytotoxicity is observed compared to cells treated with free drug.  
 iv 
To explore a different imaging modality, we investigate a new MRI platform, 
chemical exchange saturation transfer (CEST), using self-assembling drug nanofibers as 
a potential image-guided drug delivery system. CEST enables anticancer drugs with 
exchanging protons to serve as a modality reporter, thereby exhibiting both therapeutic 
and imaging capabilities. To increase retention time at the targeted site upon local 
injection, a customized peptide sequence was covalently linked to the anticancer drug, 
forming cylindrical nanofibers with hydrogel characteristics. Employing an anticancer 
drug with intrinsic CEST MRI signals, in vitro and in vivo studies show that real-time 
monitoring of drug distribution is feasible.  
To further demonstrate the prospect of anticancer drugs as a molecular building 
unit, we study the self-assembly behavior of natural and synthetic drug amphiphiles into 
discrete nanostructures. We showed the direct assembly of two amphiphilic drug 
molecules, methotrexate and folic acid, in different solvent conditions. Interestingly, folic 
acid exhibits stronger self-assembly behavior via Hoogsteen hydrogen bonding while 
methotrexate was unable to assemble into any well-defined nanostructures, despite their 
similarity in chemical structure.  
These findings demonstrate the feasibility and potential of utilizing peptide-based 
systems to transform anticancer drugs and imaging agents into discrete nanostructures 
with customizable properties. While the rational design of molecular amphiphilicity is 
essential in governing the self-assembly process, the selection of peptide sequences, as 
well as the processing conditions, is equally crucial in defining the final self-assembled 
morphology. The systems studied in this thesis open up innovative opportunities to 
exploit new functional and structural features of anticancer drugs and diagnostic probes. 
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acetate. (D) CD spectra of qCPT-Sup35 in H2O (solid line, 50 M), where nanotubes are the dominant 
self-assembly morphology, and qCPT-Sup35 in 50% aqueous MeCN after lyophilization from HFIP 
(dashed line, 50 M). The latter process of solution preparation favors the formation of single filaments 














1.1 Background and motivation 
Cancer is a category of diseases that comprises of one major characteristic, the 
uncontrollable growth and spread of mutated abnormal cells. It can be caused by internal 
factors such as inherited genetic mutations, hormones, immune conditions and external 
factors such as tobacco, infectious organisms, and unhealthy diet. For example, women 
with a family history of breast cancer possess higher risk to develop breast cancer 
throughout their life time and smokers are 25 times more likely to develop lung cancer 
compared to nonsmokers. In 2015, the estimated death caused by cancer in US alone is 
589,430 people, or about 1,615 American per day. On top of this, there are approximately 
1,658,370 new cancer cases expected to be diagnosed in 2015.
1
 
Although years of dedicated research and billions of dollars of investment have 
significantly increased our understanding on the cause and biology of cancer, the 
development in cancer diagnostics and therapeutics is still limited by several challenges. 
For example, in cancer diagnostics, optical-based activatable molecular probes, such as 
molecular beacons with peptide degradable linkers have been devised to detect the 
overexpression of cancer protease activity.
2,3 
However, the peptide linkers which are 
crucial in reporting signal, typically are exposed to the physiological environment and 
their facile degradation by non-specific enzymes often give rise to an undesired false 
signal, thus limiting the accuracy of enzyme detection. Apart from that, cancer 
therapeutics also faces challenges in achieving high therapeutic effect. Small molecule 





In addition, non-specific delivery of these anticancer drugs to 
both normal and cancer cells is the major cause for drug’s side effects. Although 
numerous nanoparticulate systems have been established in an attempt to address these 




 The objective of this work was to develop a versatile system to address the issues 
stated above for cancer diagnostic and cancer therapeutics. Our approach was to 
incorporate a peptide-based system to existing anticancer drugs and imaging modalities 
that ultimately transforms molecular system to nanostructure, harnessing some of the 
advantages offered in the realm of nano-scale. Specifically, nanostructure enables passive 
targeting through enhanced permeability and retention effect as well as cargo protection 
by embedding molecules of interest within the core of nanostructure. 
1.2 Nanomedicine for diagnostic and drug delivery applications 
1.2.1 The emergence of nanomedicine 
Nanomedicine, a term that first emerged in the year 2000, focuses on using 
nanotechnology approaches for medical applications. By definition, nanotechnology 
comprises of objects in the dimension of nanometer, ranging from 1 nm to 100 nm. At 
this nanometer and atomic level scale, materials could exhibit enhanced properties due to 
the increased surface area and quantum effects, which is otherwise unattainable at the 
larger scale.
6 
For example, quantum dots (QDs) fluorescence emission wavelength can be 
tuned from blue to near infrared by manipulating the particle’s diameter as a result of the 
usually high surface-to-volume ratio and quantum confinement.
7 
QDs with 4 nm in 
diameter will fluoresce green while 6.5 nm QDs fluoresce red
8
, and they have shown 
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greater photostability than traditional fluorescence dyes.
9 
On the other hand, iron oxide 
nanocrystals were found to exhibit superparamagnetic properties that can be used as 
contrast agents for magnetic resonance imaging (MRI). With an iron core of 
approximately 4-5nm, its induced magnetic disturbance causes a reduction in T2 
relaxation time of nearby water protons resulting in a loss of local signal intensity.
10 
Another example of utilizing nanotechnology in diagnostic applications is the gold 
nanoparticle, which has the ability to serve as a quencher in Förster resonance energy 
transfer measurement studies. With this approach, researchers were able to evaluate the 







Figure 1-1. Nanomedicine platform offers a variety of properties that enable designers to 
customize therapies and imaging systems, ultimately improving the chances of clinical 
translational. Adapted with permission from Ref. 13 (Copyright © 2013 AAAS) 
In addition to inorganic-based nanoparticles, various organic materials have been 
used to generate nanostructures for cancer diagnostic and drug delivery purposes. For 
instance, liposome composed of phospholipids has been utilized for gene, 
chemotherapeutic drugs, and contrast agents delivery.
14-17 
Besides, a number of 
polymeric-based micelles systems have been developed as the carrier or vehicles for 
chemotherapeutic drugs and imaging modality. In general, hydrophilic and hydrophobic 
block copolymers were designed to encapsulate or conjugate molecules of interest to 
induce the micelle formation.
18,19 
Another type of organic-based nanoparticle is the 
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dendrimer, a spherical nanosized tree-architecture that can attach multiple drugs, contrast 
agents, and targeting ligands.
20,21 
 
1.1.2 Passive targeting 
One of the advantages offered by nanomedicine is the passive targeting, an 
accumulation of particles at the tumor site owing to its nano size. Due to the elevated 
nutrient requirement from abnormal growth of cancerous tissues, the formation of new 
blood vessels around the tumor site, also known as angiogenesis, is often impaired and 
leaky. The defective angiogenesis was shown to increase permeability of nanostructures, 
where the gap between the blood vessel’s endothelial cells could be as large as 300 nm – 
800 nm while normal endothelial cells were well aligned with the gap size of ~2 nm. In 
addition, the tumor site was found to have a dysfunctional lymphatic drainage system, 
where extravasated nanoparticles could have a longer retention time and enabled drug 
release close to tumor cells. This phenomenon is termed as the enhanced permeability 
and retention (EPR) effect where nano-sized systems could achieve passive targeting to 
the tumor site for diagnostic or drug delivery purposes.
22,23 
Although the gap of leaky 
blood vessels could be as large as 800 nm, other considerations should be taken into 
account when designing the size of nanoparticles to overcome numerous physical barriers 
such as mucosal entrapment, immunogenicity, and non-specific uptake. For instance, 
nanoparticles of larger than 200 nm in size encounter stronger opsonization, which 
surface deposition of blood opsonic factors would aid particle recognition by 
macrophages resulting in rapid clearance of nanoparticles in the blood stream.
24 
On the 
contrary, nanoparticles with sizes smaller than 6 nm can be cleared efficiently from the 





modeling showed that hemodynamic forces and other interactions acting on spherical 
nanoparticles of about 100 nm in diameter tend to keep them in the center of blood 
vessels, which could potentially decrease the chance for nanoparticles to extravasate 
through the vessel walls.
26,27 
In addition to the particle’s size, other parameters such as 
shape and surface charges of nanoparticles also govern the circulation properties in the 
blood stream, which requires in-depth physicochemical understanding for optimization.  
 
Figure 1-2. Schematic illustration of two different delivery mechanisms in which 
nanoparticles accumulate at tumor site. The increased permeability of tumor vasculature 
and ineffective lymphatic enable extravasation of nanoparticles through passive targeting 
(EPR). Active targeting (inset) is achieved by conjugating targeting ligands on the 
surface of nanoparticles which enhances cell-specific recognition and binding. Reprinted 
with permission from Ref. 28 (© 2007 Nature Publishing Group) 
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1.1.3 Active targeting 
In order to increase the specificity of nanoparticles, active targeting, also known 
as ligand-mediated targeting, selectively presents bioactive ligands on the surface of 
nanoparticles to induce binding affinity towards targeted disease cells.
29 
Upon selective 
binding of ligand to surface molecules or receptors overexpressed on diseased cells, 
nanoparticles are internalized into targeted cells and subsequently release their cargo for 
therapeutic or imaging purposes. For example, Anti-HER2 targeting ligands were 
conjugated on the surface of liposomes and were shown to increase the uptake of 
liposomes in HER2-expressing cancer cells, in contrast to the non-targeted liposomes 
which tend to accumulate in the perivascular or stromal space.
30 
With the high tunability 
of nanoparticles, researchers have shown that a combination of ligands such as folic acid 
and EGFR antibodies could be utilized to improve cellular internalization through 
multiple surface receptor targeting.
31 
Another category of ligand comes from the peptide 
family, such as the RGD (arginine-glycine-aspartic acid) peptide sequence. This peptide 
ligand can bind specifically to αvβ3 integrin receptors, and it has been used to target both 
cancer and angiogenic endothelial cells.
32 
Although RGD is a very short peptide 
sequence, its molecular geometry such as linear or cyclic RGD conformation was found 
to affect its targeting efficiency dramatically. Studies showed that cyclic RGD has a 
higher binding affinity than its linear counterpart in anti-tumor targeting.
33 
Although 
many of the actively-targeted nanoparticles have shown great promise, most of them are 
still in the stage of clinical development and have not been commercialized yet. 
Depending on the type of ligand-receptor pair, the ligand density displayed on the surface 
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of nanoparticles, ligand charge status, ligand orientation, and binding affinity highly 
affect the end results of targeting in vitro and in vivo.
29 
 
1.3 Enzyme-activatable systems for diagnostic and drug release 
1.3.1 Proteolytic enzymes in cancer 
Proteolytic enzymes regulate various biological processes such as proliferation, 
migration, cell death, invasion, and protein turnover. Through proteolysis, enzymes 
degrade protein by hydrolysis, a process to break down peptide bonds of covalently-
linked amino acids. There are at least 569 proteases in human system and they can be 
categorized into five major types of mammalian protease, namely, aspartic, cystein, 
serine, threonine, and metalloproteases.
34 
Each of these protease classes can perform 
catalytic reactions through different mechanisms. Given that proteases are highly 
regulated in DNA replication and transcription, angiogenesis, tissue morphogenesis and 
remodeling, inflammation, necrosis, apoptosis, cell proliferation and differentiation, an 
alteration in proteolytic systems could elicit multiple pathological conditions.
35 
For 
instance, the matrix metalloproteinases enzymes have been associated to promote tumor 
progression because of their role in extracellular matrix degradation.
36,37 
There is also 
increasing evidence to show that the overexpression of lysosomal cysteine protease, 
cathepsin B, C, L and S in various cancer cells may play a key role in the development 
and progression of malignant tumors.
38,39 
Tremendous efforts have been focused to target 
these pathological relevant proteases to discover new enzyme inhibitors for cancer 
therapy and develop protease-responsive drug delivery and diagnostic systems. 
Several approaches have been taken to construct materials or systems that are 





The enzymatic-responsive system has gained much interest in the 
community given its biological relevance and high potential in biomedical applications in 
diagnostic and drug-delivery.
42 
Enzyme catalysis was recognized for a few advantages 
over other stimuli. First, enzymes are highly selective towards their catalysis reactions, 
demonstrating high specificity in reporting a biological event. Second, enzymes work 
under mild and physiological conditions such as 37 
o
C, aqueous environment and pH 5-8. 
Third, several enzymes have been reported to serve as important modulators in healthy as 
well as diseased biological pathways. These features enable enzymes to serve as a target 
or biomarker for responsive cancer diagnostic and drug delivery systems.  
1.3.2 Enzyme-activatable drug delivery systems 
Similar to the concept of zymogen, which exists in an inactive form of enzyme 
where protease cleavage of a specific peptide sequence to convert it into its active form,
43 
drugs or diagnostic probes can be designed to incorporate enzyme-targeting peptide 
substrate for controlled release and enzyme detection. For instance, cathepsin B protease 
was found to involve in various cancer progressions and metastasis.
38,44 
Peptide substrate 
such as Gly-Phe-Leu-Gly can be used as an enzyme linker to probe the activity of 
cathepsin B and construct a system with an enzyme-triggered drug release feature.
45
 
Since the system can only be activated by a specific enzyme at the disease site, this 
strategy could reduce the toxic side effects and potentially increase the therapeutic effect 
of the drug. For example, Doxorubicin (Dox), a chemotherapeutic drug was conjugated 
onto the N-(2-hydroxypropyl)methacrylamide (HPMA) polymer through Gly-Phe-Leu-
Gly linker.
46 
After the polymer-drug was internalizated into the cell, cathepsin B, which 
comes from the family of lysosomal proteases, degrades GFLG peptide linker and 
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releases Dox drug intracellularly.
47 
Another notable example is the Adcetris, also known 
as brentuximab vedotin (Seattle Genetics, WA, USA), an FDA-approved antibody-drug 
conjugate that targets cathepsin B for Hodgkin’s lymphoma (HL) and systematic 
anaplastic large cell lymphoma (ALCL).
48 
Cathepsin B cleavable peptide linkers such as 
valine-citruline and phenyalanine-lysine were used to linked monomethylauristatin E 
(MMAE) drug and monoclonal-antibody that is specific to CD30 on hematological 
malignancies. Compared to the hydrozone-sensitive linker, the antibody drug conjugates 
with protease-responsive linker was found to be more stable in plasma and exhibited 
greater in vitro specificity and lower in vivo toxicity.
49 
Remarkably, in vivo studies of this 
antibody-drug conjugate showed high efficiency in tumor induced regressions with 
therapeutic indices as high as 60-fold, which is significantly higher than other mAb-drug 
conjugates. The biomolecular specificity offered by antibody as well as enzymatic-
responsive activation has been shown to enhance drug efficacy and reduce 




Figure 1-3. Nanomaterials with enzymatic-responsive feature for drug delivery and 
diagnostic. a) Enzyme activity triggers drug release by cleaving enzyme-specific linker 
conjugated to polymer-based nanoparticles. b) Drug-loaded polymer-stabilized 
liposomes,whose drug release can be programmed to be triggered by an enzyme. c) The 
assembly and disassembly of inorganic nanoparticles can be controlled by enzymatic 
activity, which changes the physical properties of the nanoparticle for diagnostic 
purposes. Adapted with permission from Ref. 42. (© 2012 Elsevier) 
1.3.3 Enzyme-activatable diagnostic and imaging systems 
In addition to drug delivery applications, enzyme-activatable probes are employed 
in various cancer diagnostic systems to image tumor in vivo. For example, Weissleder 
and coworkers have developed a near-infrared fluorescent (NIRF) probe that can be 
activated by lysosomal protease in vivo.
50 
Multiple NIRF molecules were conjugated onto 
the poly-L-lysine side chain of a synthesis graft copolymer, which exhibit a self-
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quenching state (Off-state) due to close proximity of each NIRF molecules. However, 
upon internalization into cells, lysosomal cystein/serine protease such as cathepsin B, H 
and L activate the probe by degrading the poly-L-lysine backbone, therefore fluorescence 
resumed for detection and imaging (On-state). With this design, the fluorescence signal 




Besides conjugating to polymer
51
, cathepsin B-responsive features have been 









, and peptide-based systems.
57,58 
The vast 
exploration of enzymatic-responsive biomaterials and systems demonstrated its interest 
and potential for future applications. 
1.4 Self-assembly of peptide-based supramolecular nanostructures 
1.4.1 The nature of self-assembly 
 Self-assembly is a process in which individual molecules or components 
spontaneously form ordered aggregates when the appropriate conditions are met. In 
general, there are two types of self-assembly: static and dynamic.
59 
In static self-
assembly, systems exist at a global or local equilibrium and do not involve any energy 
dissipation. However, some form of energy such as mixing and stirring may be required 
to form the stable ordered structure. For example, the self-assembly of molecular crystals 
and the folding of globular proteins are in the categories of static self-assembly.
60-63 
In 
contrast, dynamic self-assembly refers to the organization of structures when the system 
is deliberately kept away from its energy minimum (non-equilibrium state) by continuous 
energy supply and dissipation.
64 
As a result, it alters the interactions of 
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molecules/components with each other and with their environment. Numerous biological 
systems such as the formation of living cells
65
, schools of fish, and armies of ants
66
 
undergo dynamic self-assembly, which is in nature more challenging to understand than 
static self-assembly as it cannot be predicted through energy minimization.
67
 
1.4.2 The driving forces of peptide self-assembly 
 In general, self-assembled peptide-based nanostructures are driven and stabilized 
by non-convalent bonds. These driving forces typically include hydrogen bonds, ionic 
bonds, π-π interactions, hydrophobic and van der Waals interactions. To sustain the stable 
and well-defined nanostructures, these molecules interact inter- and intramolecularly 
through a collective of interactions. These self-assembled nanostructures are generally 
thermodynamically favorable; therefore, they exist at a stable or meta-stable state. 
 To construct a one-dimensional or cylindrical shape nanostructure, such as 
nanofibers or nanotubes, hydrogen-bonding typically played a crucial role in directing the 
growth of nanostructure. A molecular simulation done by Velichko et. al. showed that 
strong hydrophobic interaction without hydrogen bonding leads to the formation micelles 
of finite sizes.
68 
On the other hand, systems with exclusively hydrogen bonding favors 1-
D β-sheet structure forming through step-by-step aggregation of molecules. In the 
presence of both hydrophobic interaction and hydrogen bonding, the final self-assemblies 
largely depend on the strength of intermolecular bonding and the self-assembly kinetics 
may take a longer time to reach equilibrium. With a stronger hydrophobic interaction, 
molecules may first self-assemble into spherical micelles with random β-sheet scattered 
around the corona. As the hydrogen bonding energy increases, the ordering of β-sheet 
disrupts the spherical interfacial curvature of micelle and further elongated forming a 1-D 
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nanofiber. Experimentally, Hartgerink and coworkers also studied the effect of hydrogen 
bonding in directing the final self-assembled nanostructure.
69 
They found that the 
disruption of hydrogen bonding through modifying the four amino acids closest to the 
core would lead to the formation of spherical micelle instead of nanofibers. This finding 
is in good agreement with Velichko’s simulation which showed the importance of 
hydrogen bonding in the formation of 1-D nanostructure. 
 
Figure 1-4. Schematic phase diagram illustrates the effects of hydrophobic attraction and 
hydrogen bonding implied by simulation results. The phase diagram shows regions with 
(a) free molecules, (b) spherical micelles, (c) micelles with β-sheets on the outside 
forming the corona, (d) long cylindrical fibers, (e) stacks of parallel β-sheets, (f) single β-
sheets, and (g) the amorphous aggregate phase. Reprinted with permission from Ref. 68. 
(Copyright © 2008 American Chemical Society) 
 
 15 
1.4.3 Rational design of self-assembling peptide molecule 
The peptide-based system is highly versatile when given that each of the 20 
common amino acids offers different properties such as hydrophobicity, hydrophilicity, 
functional group and charged or non-charged side chains. This allowed scientists and 
engineers to design and customize peptide molecules to self-assemble into different 
shapes of nanostructures such as spherical, cylindrical, vesicle and tubular, as well as 
demonstrating different functionalities for diagnostic, drug delivery, and tissue 
regenerative applications.
70-74 
For instance, self-assembling peptide amphiphile typically 
composed of 4 regions, namely the hydrophobic domain to induce self-assembly, 
hydrophilic amino acids to aid molecule solubility in water, short peptide with high 
tendency of forming intramolecular hydrogen bonding, and bioactive epitope to enhance 
cells or protein interaction.
75 
The basis of this design relies on the amphiphilic nature of 
the molecule, in which having a hydrophobic end of alkyl tail and grouping hydrophilic 
amino acids on the opposite site of the sequence to induce the self-assembly process.
72 
To 
direct the self-assembly into one-dimensional cylindrical nanofibers, a hydrogen-bond 
forming sequence was incorporated into the design for stronger beta-sheet interaction. By 
presenting bioactive epitopes on the surface of nanofibers (similar to the concept of 
active targeting), self-assembling nanofibers were shown to foster cell adhesion using 






Figure 1-5. a) Molecular structure of a representative peptide amphiphile with four 
rationally designed chemical entities. (b) Molecular graphics illustration of an IKVAV-
containing PA molecule and its self-assembly into nanofibers. (c) Scanning electron 
micrograph of the IKVAV nanofiber network formed by adding cell media (DMEM) to 
the PA aqueous solution. (d) Transmission electron micrograph of the IKVAV 
nanofibers. Adapted with permission from Ref. 76 (© 2004 AAAS) and Ref. 74 (© 2003 
American Chemical Society). 
Peptide can also be rationally designed to adopt a specific secondary 
conformation that would lead to the self-assembly of higher hierarchy structures such as 
nanofibers and hydrogel. Schneider and colleagues showed that peptide sequence with 
high β-sheet propensity amino acids and inducible β-hairpin structure would undergo 
self-assembly process to form nanofibers further associated into hydrogel scaffold.
78 
This 
β-hairpin peptide model can be achieved by flanking (-VDPPT-) tetrapeptide at the center 
of the 20-residue long peptide. By manipulating the charge status of lysine under basic 
conditions, the designed peptide would intramolecularly fold into β-hairpin structure to 
present one face lines with hydrophobic valine residues and another face lines with 
hydrophilic lysine residues, an amphiphilic arrangement of the peptide. This folding 
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process or peptide conformation is reversible by lowering the pH to increase charge 
repulsion between neighboring lysine residues. 
Another group of peptide self-assembly was termed as “molecular Lego” by 
Zhang and coworkers.
79 
Similar to the Lego bricks that have pegs and holes, peptides 
were designed to present two separate faces with hydrophilic and hydrophobic nature, 
which would assemble at the molecular level. Focusing on the ionic charge arrangement, 
peptides were designed with regular repeats of alternating positively- and negatively-
charged amino acids to systematically form complementary ionic bonds with the 
neighboring peptides. The pattern of cationic and anionic alteration can be classified into 
different moduli, such as modulus I with - + - + - + - +, modulus II with - - + + - - + + 
and modulus IV with - - - - + + + +.
80798058585858
 The precise array of sequence enables 
these peptides to self-assemble in a well-ordered manner, mainly driven by its 
amphiphilicity as well as ionic interaction.  
One of the common features in designing self-assembling peptide emphasizes the 
amphiphilic nature of the molecule. Distinctly grouping hydrophobic and hydrophilic into 
different faces facilitates the self-assembly process, and most importantly, enables the 
formation of discrete nanostructures.  
1.5  Thesis Overview 
This thesis aims to describe a platform that ultimately transforms anticancer drugs and 
imaging probes from molecular-level to nano-level constructs. The emphasis of 
nanostructure offers several advantages that could potentially address current limitations 
in cancer diagnostics and therapeutics. Through a rational design of the peptide-based 
system coupled with an in-depth understanding of molecular chemistry, this thesis covers 
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several examples that illustrate the construction of diagnostic nanoprobes and therapeutic 
nanofiber hydrogel. Chapter 2 and Chapter 3 highlight the design and importance of 
nanobeacon diagnostic probe in spherical and cylindrical shapes. Chapter 4 illustrates the 
construct of drug beacon that comprises of both diagnostic and therapeutic 
functionalities. Next, Chapter 5 describes the formation therapeutic nanofiber hydrogel 
with magnetic resonance imaging properties. In the following Chapter 6, I investigate the 
self-assembly of natural and synthetic drug amphiphiles into discrete nanostructures. 
Lastly, Chapter 7 presents the conclusions as well as potential future work to improve 




2 Design and Construction of Supramolecular 
Nanobeacons for Enzyme Detection
*
 
2.1  Abstract 
Molecular beacons are typically water-soluble molecules that can convert specific 
chemical reactions or binding events into measurable optical signals, providing a 
noninvasive means to help understand cellular and subcellular activities at the molecular 
level. However, the soluble form of the current molecular beacon design often leads to 
their poor stability and facile degradation by nonspecific enzymes, and as a result, this 
undesired activation could give rise to false signals and thus poses a limitation for 
accurate detection of enzymatic activities. Here we report a proof-of-concept design and 
synthesis of a new type of supramolecular nanobeacon that is resistant to nonspecific 
enzymatic degradation in the self-assembled state but can be effectively cleaved by the 
target enzyme in the monomeric form. Our results show that the nanobeacon with a 
GFLG peptide linker could serve as an indicator for the presence of a lysosomal enzyme, 
cathepsin B.  
2.2  Introduction 
Real time detection of the location and expression level of enzymes within living 
cells offers important information on many important cellular and subcellular events and 
                                                 
 
*Reprinted with permission from Lock, L.L.; Cheetham, A. G.; Zhang, P.; Cui, H., ACS Nano, 2013, 7 (6), 
4924-4932. Copyright ©2013 American Chemical Society 
 
L.L.L., C.A.G., Z.P., and C.H. designed the experiments. L.L.L. performed all experiments and analyzed 
the data.  L.L.L. and C.H. prepared the manuscript. 
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thus provides unique opportunities for the development of new strategies for tumor 
diagnosis and cancer therapeutics.
2,50,81,82  
The overexpression and relative abundance of 
certain proteases in cancers, such as cathepsins and matrix metalloproteases (MMPs), 
provide attractive targets for tumor screening.
50,82,83 
In the design of polymer-drug 
conjugates with peptide linkers, enzymatic cleavage is an important step towards the 
release of bioactive anticancer drugs, with the release rate being a function of active 
enzyme concentration.
84-86 
Recently, there is also a rapidly growing interest in the 
development of enzymatically responsive materials.
87-98 
 Therefore, it is important and 
necessary to precisely detect the activities or expression levels of enzymes of interest. 
The advent and development of activatable molecular probes, such as molecular 
beacons that contain a fluorophore and quencher pair, have enabled possibilities for the 
highly sensitive detection of DNA/RNA through the conversion of specific binding 
events into detectable fluorescence signals.
99-101 
 Very recently, molecular beacons with 
proteolytically degradable peptide linkers have been devised for protease detection and 
other applications.
2,3,87,102-105 
However, since the linkers that are designed to activate 
molecular beacons are typically exposed to the physiological environment, their poor 
stability and facile degradation by non-specific enzymes often give rise to an undesired 
false signal and thus pose a major limitation for accurate detection of enzymatic 
activities. 
To develop molecular probes immune to undesired degradation, we report here a 
generic design platform of a new type of self-assembling supramolecular nano-beacon 
(NB) with a well-defined size and surface chemistry for protease detection. In contrast to 
soluble molecular beacons, the NB molecules are specifically designed to self-assemble 
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into core-shell micelles, with the enzyme-sensitive design feature being deeply embedded 
within the micellar core and thus inaccessible to the enzyme (Fig. 2-1A). Only in the 
monomeric form can these NB molecules be cleaved by the target enzyme to generate 
fluorescence signals. 
 
Figure 2-1. Schematic illustration of the expected cleavage and detection mechanism (A) 
and molecular structure of the designed nano-beacon molecule TFB (B). In the self-
assembled state, the enzyme-sensitive linker is deeply buried in the micellar core, while 
in the monomeric form, the NB molecules become accessible for enzymatic cleavage. 
The designed molecule exists in the self-assembled NB form above its critical 
micellization concentration (CMC). The transition from NB micelles to monomeric form 




2.3  Experimental Procedures 
2.3.1  Molecular Synthesis  
In brief, the Tat sequence and the peptide linker (Fmoc-
GFLGK(Mtt)GRKKRRQRRRPPQ-Rink) of the TFB molecule was first synthesized on 
an automatic peptide synthesizer (details of synthesis can be found in the supporting 
information) using standard 9-fluorenylmethoxycarbonyl (Fmoc) solid phase synthesis 
protocols. After removal of the Fmoc protecting group, 5-FAM was manually coupled at 
the peptide N-terminus. Next, Black Hole Quencher-1 (BHQ-1) was incorporated onto 
the lysine -amine, following removal of the Mtt protecting group for lysine side chains. 
The completed peptide was cleaved from the Rink Amide resin using a mixture of 
TFA/TIS/H2O.  The two control molecules: TF and TB were synthesized by using acetic 
anhydride to replace the BHQ-1 and the 5-FAM segments with an acetyl group, 
following the same procedures for the synthesis of the TFB molecule. All the molecules 
were purified using preparative RP-HPLC and their purity was evaluated by analytical 
HPLC and MALDI-ToF mass spectrometry. 
2.3.2  Cathepsin B Degradation Experiments 
The reaction buffer containing 1 mM EDTA (enzyme stabilizer) and 25 mM L-
cysteine (enzyme activator) in 1×PBS solution was prepared. The solution pH was 
adjusted to 5.0 through the addition of 3 M HCl. The desired amount of cathepsin-B was 
added to the buffer solution and pre-incubated at 37°C for 5 minutes to activate the 
enzyme. Stock solution was prepared by dissolving 0.6 mg of TFB molecule with 500 µL 
of pH 5.0 reaction buffer, yielding a TFB concentration of 0.4 mM. 0.25 µL of 0.4 mM 
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stock solution was added to each reaction well and mixed thoroughly with the pre-
incubated cathepsin-B solution. Cathepsin-B (Bovine Spleen) was purchased from EMD 
Chemicals (Gibbstown, NJ) and it was delivered in liquid form with stock concentration 
of 17 µM. Reaction kinetics was monitored using a Gemini XPS microplate reader 
(Molecular Devices, Sunnyvale, CA). Samples were excited at 492 nm and 5-FAM 
emission was measured at 520 nm with a 515 nm cutoff.  
2.3.3  kcat/KM Calculation 
The catalytic reaction of CatB has been reported to follow the kinetic behavior 
described by the Michaelis-Menten equation. According to Michaelis-Menten Equation, 
the reaction rate V can be expressed in the following form: 
  
           
      
 
in which kcat is the first-order rate constant, [E]t is the total enzyme concentration, [S] is 
the substrate (TFB, in the case reported here) concentration, and KM is the Michaelis-
Menten constant. At the very low substrate concentrations reported herein ([S]<<KM), the 
equation can be rewritten as: 
  
    
  
        
The ratio of kcat/KM provides a direct measure of enzyme efficiency and specificity. 
2.3.4  Cell Culture 
Human breast adenocarcinoma cell line, MCF-7 was kindly provided by Wirtz 
Lab at Johns Hopkins University, and was grown in Dulbecco’s Modified Eagle Medium 
(DMEM, Invitrogen) containing 10% of Fetal Bovine Serum (FBS, Invitrogen) and 1% 
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of penicillin and streptomycin (Invitrogen). This breast cancer cells were incubated at 
37
o
C in a humidified incubator with a 5% CO2 atmosphere in all the cell experiments. 
2.3.5  Cytotoxicity Assay 
The cytotoxicity of the TFB was evaluated on MCF-7 cells to make sure that the 
cells were healthy in the following experiments. Briefly, MCF-7 cells were seeded onto a 
96-well plate at a density of 5 × 10
3
 cells/well, and allowed to attach overnight. The 
medium was replaced with fresh complete medium (as described in cell culture protocol) 
containing 0, 1, 5, or 10 μM TFB and incubated for 4 hours. Then, the medium was 
changed to fresh complete medium and incubated for another 48 hours, and the cell 
viability was evaluated using Sulforhodamine B (SRB) based method according to the 
manufacturer’s protocol (TOX-6, Sigma). 
2.3.6 Flow Cytometry Measurement 
The time-dependent fluorescence increase on MCF-7 was quantified using flow 
cytometer (FACSCalibur, BD). MCF-7 cells were seeded onto a 24-well plate at density 
of 1 × 10
5
 cells/well, and allowed to attach overnight. The medium was replaced with 
fresh complete medium containing 5 μM TFB and incubated for 0.5, 1, 1.5, 2, and 2.5 
hours. Then, the cells were washed 1 time with DPBS, and further treated with Trypsin to 
harvest cells from each well. Finally, MCF-7 cells were washed 3 times with ice-cold 
DPBS, and immediately analyzed using flow cytometer at FL1 channel. The viable cells 
were gated according to forward scatter (FSC) vs. side scatter (SSC) profile, and the data 
was analyzed using Cell Quest Pro software. 
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2.3.7  Confocal Imaging 
The time-dependent fluorescence increase in MCF-7 cells was imaged using a 
confocal laser scanning microscope (CLSM, LSM 510, Zeiss) leaving the pinhole wide 
open. Briefly, MCF-7 cells were seeded onto a collagen (Invitrogen) coated 8-chamber 
glass bottom plate (Lab-Tek) at a density of 3 × 10
4
 cells/well, and allowed to attach 
overnight. The medium was replaced with fresh complete medium containing 5 μM TFB. 
After 0.5 and 1.5 hours incubation, the cells were washed 3 times with DPBS, and fixed 
with 100 μL of 4% paraformaldehyde for 10 min at 4 
o
C. Then, the paraformaldehyde 
was removed and the cells were washed 3 times with DPBS. In the colocalization 
experiment, the cells were seeded and treated in the same manner except 100 nM 
Lysotracker Red (Invitrogen) and 5 μg/mL Hoechst 33342 (Invitrogen) were added to 
stain the lysosome and nucleus, respectively. These two dyes were added 20 min before 
cell fixation. Finally, 100 μL of Fluomount-G (Southernbiotech) was added, and the 
samples were imaged immediately using CLSM (pinhole sizes were set to obtain optical 
slice at 0.9 μm). 
2.4  Results and Discussions 
2.4.1  Molecular Design  
The core concept of the design is to construct an amphiphilic NB molecule having 
the potential to self-assemble into nano-objects under physiological conditions. This 
amphiphilicity is achieved by conjugating a hydrophobic quencher and a dye onto a 
hydrophilic peptide. The concept of attaining amphiphilicity by means of conjugating two 
or more small-molecular chemical moieties with distinct solvent selectivity has been used 
to successfully construct peptide amphiphiles,
69,106-109





and amphiphilic molecules with π-conjugated segments.111-113 Fig. 2-1B 
shows the chemical structure of the proof-of-concept NB molecule studied in this paper. 
First of all, the hydrophobic units are composed of a black hole quencher BHQ-1, and a 
green dye, 5-carboxyfluorescein (5-FAM). 5-FAM was chosen on the basis of its 
exceptionally high quantum yield in the visible light region. The BHQ-1 segment with 
broad absorption between 400-650 nm (major absorption between 480-580 nm) will, 
when placed in close proximity to 5-FAM, quench the 5-FAM fluorescence without 
generating fluorescence of its own, thereby offering a high signal-to-noise ratio. Second, 
a HIV-1 derived cell penetrating peptide Tat48-60,
114 
with positively charged arginine and 
lysine amino acids, was incorporated as the hydrophilic segment to allow effective 
penetration of the cell membrane. The weakly basic nature of the arginine and lysine 
residues allows for the design of pH-responsive supramolecular nanobeacons. Finally, the 
key and most critical component is the cleavable linker that bridges 5-FAM and the 
lysine N terminus. The peptide tetramer of -Gly-Phe-Leu-Gly- (GFLG), first identified by 
Kopecek, Duncan and coworkers,
84,85 
can be effectively cleaved by cathepsin B (CatB), a 
lysosomal protease involved in cellular protein turnover and degradation. We choose 
CatB because it plays important roles in tumor growth and progression and serves as a 
potential marker for tumor screening.
50,83,115-117 
CatB has also attracted considerable 






Figure 2-2. Photographs of 200 µM aqueous solutions of TFB (A), TF (B) and TB (C), 
and their respective molecular structures. The effective quenching of 5-FAM fluorophore 
by the BHQ-1 segment is reflected in the dramatic color change from bright green (B) to 
dark red (A). (D) 5-FAM fluorescence measurements of 1µM TF and 1µM TFB aqueous 
solutions. 
2.4.2  Quenching Effect  
We synthesized two control molecules: TF (Fig. 2-2B) and TB (Fig. 2-2C) to 
assist in better understanding of the quenching effect and self-assembly behaviors of the 
TFB NB molecule (S1-S2 in SI). The effective quenching of the 5-FAM fluorophore by 
BHQ-1 in the NB molecule can be inferred by a change in solution color between three 
molecules (Figs. 2-2A-2-2C). At a concentration of 200 µM, the aqueous solution of the 
TF conjugate appears bright green, owing to the 5-FAM fluorescence around 520 nm 
(Fig. 2-2B). In contrast, the aqueous solution of 200 µM TB displays a dark red color 
(Fig. 2-2C) due to the absorption in the visible light region between 400-650 nm. The 
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dark red color of 200 µM TFB solution (Fig. 2-2A), similar to that of TB solution but 
distinct from that of TF solution, strongly suggests an effective quenching of 5-FAM 
fluorescence. This effective quenching was further supported by the measurements of the 
fluorescence of the 5-FAM chromophore. It was found that the 5-FAM fluorescence 
intensity of 1 µM TFB solution drops more than 80 times relative to that of a TF solution 
of the same molar concentration (Fig. 2-2D), implying a greater than 98% efficiency of 5-
FAM fluorescence resonance energy transfer within the designed NB molecule.  
 
Figure 2-3. TEM (A) and cryo-TEM (B) images of 200 µM TFB in 1×PBS solutions 
reveal self-assembled nanoparticles of a uniform size (11.1±1.2 nm). TEM images of 
nanoparticles formed by self-assembly of 400 µM TF (C) and TB (D) in 1×PBS solutions 
with sizes of 18.4±3.7 nm, and 13.1±1.0 nm, respectively. TEM samples in (A), (C) and 
(D) were negatively stained using a 2 wt% uranyl acetate aqueous solution to enhance the 
image contrast. All scale bars: 50 nm. 
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2.4.3  Self-Assembly and Characterization  
Self-assembly was initiated by dissolution of the molecule into either Milli-Q 
water or in phosphate buffered saline (PBS). Transmission electron microscopy (TEM) 
studies showed that all three molecules, TFB, TF and TB, self-assemble into spherical 
micelles under physiological conditions, with sizes of 11.1±1.2 nm, 18.4±3.7 nm, and 
13.1±1.0 nm, respectively (Figs. 2-3A – 2-3D, and S3 in SI ). A representative TEM 
image from a 1×PBS solution of 200 µM TFB is shown in Fig. 3A, revealing dominant 
nanoparticles with a uniform size of approximately 11 nm. In this image, the 
nanoparticles appear brighter than the background due to the use of uranyl acetate as a 
negative staining agent which deposits more on the background and thus reverses the 
image contrast. The size and shape of these nanobeacons was further confirmed using 
cryogenic TEM imaging techniques (Fig. 2-3B) which involve no staining but direct 
imaging of the liquid sample solution. Since the Tat peptide is rich in arginines and 
lysines, one would expect that the self-assembly behaviors of all the three studied 
molecules are pH-dependant. Indeed, we found that TB can self-assemble into 
supramolecular filaments in borate buffer (pH 9.5) (S4 in SI) in contrast to the spherical 
nanostructures in 1PBS (pH 7.4). We believe the observed morphological transition is 
driven by the reduced electrostatic repulsions among the Tat peptides as a result of the 
deprotonation of the amines at higher pH 
Circular dichroism measurements show that the hydrophilic Tat sequence 
assumes a random coil-like secondary structure under physiological conditions (S5 in SI). 
The diameter of 11 nm is reasonably close to twice that of the expected molecular length 
of TFB. The amphiphilic nature of the TFB leads us to conclude that nanoparticles 
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observed in Fig. 2-3A are core-shell micelles with the 5-FAM and BHQ-1 segments 
comprising the core. Since enzyme-catalyzed reactions involve the formation of enzyme-
substrate complexes, the fact that the –GFLG- linkers are deeply embedded within the 
micellar core suggests that in the assembled state the –GFLG- peptide linkers would be 
inaccessible to CatB for cleavage. 
 
Figure 2-4. Fluorescence monitoring of the degradation process of NBs by CatB. (A) 
Time-course fluorescence measurements of a 3 μM TFB 1×PBS solution in the presence 
of 1 μM CatB; (B) photographs of NB solutions before and after CatB cleavage; (C) 
fluorescent measurement of 1 µM TFB PBS solutions in the presence of various 
concentrations of CatB; (D) plot of initial rate of 5-FAM cleavage versus CatB 
concentration (square, 1 µM TFB; circle, 50 µM TFB). The red and blue lines show a 
linear fit for the obtained data. 
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2.4.4  Enzymatic Degradation  
Digestion experiments were carried out to evaluate the degradation kinetics of 
TFB NBs by CatB (S6 in SI). In these experiments, CatB was first activated for 5 mins at 
37
o
C using a reaction buffer containing 1 mM EDTA and 25 mM L-cysteine. All 
solutions were adjusted to pH 5.0 to ensure proper CatB function. NB from a stock 
solution (1mM) was then introduced to solutions containing the desired amount of 
activated CatB, and the solution fluorescence was subsequently monitored. 
Fig. 2-4A shows that in the presence of only 1 µM CatB the fluorescence intensity 
rapidly increases with time, with an approximate 25-fold increase in the peak intensity at 
520 nm within 80 mins. After a sufficient time for cleavage, the solution color was 
observed to change from light red to light yellow (Fig. 2-4B). The small fluorescence 
peak in the absence of CatB arises from incomplete quenching of 5-FAM, and its 
intensity did not change over time, suggesting that the TFB molecules are rather stable 
under the experimental conditions. It is also important to note that when MMP-2 was 
added to the TFB NB solution, no noticeable cleavage reaction was observed throughout 
the course of 4 hour incubation (S7 in SI). 
In order to correlate the fluorescence intensity to the enzyme activity and also to 
understand the enzyme cleavage efficiency on the studied NB molecule, we performed a 
series of experiments on 1 µM TFB solutions while varying the amount of CatB added. 
The 1 µM concentration is far below the critical micellization concentration (CMC) of 
TFB at pH 5, which was determined to be around 30 µM using a surface tension 
measurement method (S8 in SI). Fig. 2-4C clearly reveals that an increase in CatB 
concentration leads to faster cleavage of 5-FAM from TFB. It is also evident that 
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concentrations of CatB as low as 20 nM can effectively cleave the peptide linker, 
although the reaction proceeds at a much slower rate. 
We found that the initial rate of cleavage scales linearly with the concentration of 
CatB (Fig. 2-4D). The catalytic reaction of CatB has been reported to follow the kinetic 
behavior described by the Michaelis-Menten equation.
84,85 
At the very low substrate 
concentrations, the equation can be simplified as:       
  
       , in which kcat is the first-
order rate constant, [E]t is the total enzyme concentration, [S] is the substrate (TFB, in the 
case reported here) concentration, and KM is the Michaelis-Menten constant (S9 in SI). In 
the particular case reported herein (–GFLG- linker cleavage by CatB), the KM has been 
reported to be on the scale of mM,
84,85 
a value much higher than the 1 µM TFB 
concentration. The ratio of kcat/KM provides a direct measure of enzyme efficiency and 
specificity. The plot in Fig. 2-4D is in good agreement with this equation as the initial 
cleavage rate is indeed linear with respect to the CatB concentration. The initial reaction 
rates, V0, were obtained from the linear region at the very beginning of the curves 
presented in Fig. 2-4C. kcat/KM was calculated using this simplified Michaelis-Menten 




 (S9 in SI). This value 
shows a reasonable degradation efficiency of the -GFLG- linker to CatB digestion. This 
finding also implies that quantitative detection of CatB in live cells is possible once 
accurate measurements of the initial reaction rate and the local concentration of the 
delivered NBs can be obtained. 
We performed further experiments on a series of TFB solutions of different 
concentrations with a fixed CatB concentration (S10 in SI). We found that the initial 
cleavage rate first increased with the increase of TFB concentration from 50 nM to 1 µM 
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as expected according to Michaelis-Menten equation but then started to drop after 3 µM. 
We attribute this drop in cleavage rate to the formation of dimers, trimers or other TFB 
molecular clusters that prevent the NB from being effectively cleaved by CatB. In order 
to gain a better understanding of the degradation kinetics of TFB micelles, we carried out 
experiments on a 50 µM TFB solution, a concentration above the CMC (~30 µM). As 
expected, the cleavage reaction was found to proceed much more slowly, and the kcat/KM 




 (Figs. 2-4D and S9 in SI), a value almost 
three orders of magnitude lower than that of CatB cleavage on the TFB monomers. Since 
TFB predominantly exists in aggregates above the CMC, these results clearly suggest that 
the -GFLG- peptide linker is inaccessible for effective CatB cleavage, and thus provide 




Figure 2-5. Time-dependent fluorescence of NB molecules inside MCF-7 human breast 
cancer cells. Fluorescence images of cells after 0 h (A), 0.5 h (B) and 1.5 h (C) exposure 
to TFB NB show increased 5-FAM fluorescence with time. The cell nuclei were stained 
with the blue dye Hoechst 33342. (D) Flow cytometry confirms the increased 
fluorescence intensity with time inside live MCF-7 cells. 
2.4.5  Cancer Cell Imaging  
To assess the possibility of using the designed NB for detection of CatB activities 
in cells, MCF-7 human breast cancer cells were incubated with 5 µM TFB at 37oC in cell 
media, and fluorescence images on the basis of 5-FAM emission were taken at different 
time points (0 h, 0.5 h, and 1.5 h) (S11 in SI). Figs. 2-5A-C reveals increased 5-FAM 
fluorescence intensity inside the MCF-7 cells with increased incubation time. Since intact 
TFB molecules remain dark and are not fluorescent, this result reveals that the NB 
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molecule is not only capable of entering the cells but can also be effectively activated 
within cells to generate green fluorescence. 
To confirm the observed 5-FAM fluorescence does not stem from potential 
artifacts associated with cell fixation, we used flow cytometry to investigate the time-
dependant fluorescence in live cells (Fig. 2-5D). These results are consistent with the 
fluorescent imaging data. The continuous increase in fluorescence intensity with 
prolonged incubation time suggests effective cellular uptake of NB molecules. We 
speculate this effective internalization might be a combined effect of using the Tat cell 
penetrating peptide with the amphiphilic design of the NB molecule. A linear correlation 
of the geo-mean fluorescence intensity versus time was observed (Fig. S11 of S11 in SI), 
however, this correlation should be interpreted with caution and cannot be used to 
directly quantify CatB within cells because it is not clear whether the cellular uptake or 
the CatB cleavage reaction is the rate-limiting step, and whether other factors such as pH 
or ionic strength also contribute to the florescence intensity.  
To evaluate if the internalized TFB NBs were indeed cleaved by the CatB 
enzyme, a CatB inhibitor (CA-074 Me) was used to suppress the CatB activity in cells. 
Both of our fluorescence and flow cytometery experiments reveal that the 5-FAM 
fluorescence intensity is significantly reduced in the presence of the inhibitor (Figs. S12-
S13 of S11 in SI). We also performed experiments to show that the inhibitor does not 
interfere with the cellular uptake of the TFB and the viability of the studied cells (Figs. 
S14-S15 of S11 in SI). These experiments clearly suggest the specific cleavage of TFB 
NB by CatB. Colocalization experiments were also performed to verify the locations 
from where the 5-FAM fluorescence was generated. Lysosomes of MCF-7 cells were 
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labeled with Lysotracker Red. As shown in Fig. 2-6, the merged fluorescence image (Fig. 
2-6C) shows almost complete overlap of the 5-FAM green fluorescence with the 
Lysotracker Red fluorescence, indicating the 5-FAM fluorescence arises from lysosomes 
where CatB is expected to reside. 
 
Figure 2-6. Confocal fluorescent images of MCF-7 cells after 2.5 h incubation with NB 
molecules show colocalization of the fluorescence signal of 5-FAM with that of the 
Lysotracker Red. (A) Image of 5-FAM fluorescence. (B) Image of Lysotracker Red 
fluorescence, and (C) merged image of (A) and (B). The cell nuclei were stained with the 
blue dye Hoechst 33342. 
For the TFB concentrations used in all these studies, cell viability tests shows the 
TFB NB has little toxicity to MCF-7 cells during the incubation (Fig. S17 of S11 in SI). 
However, for concentrations higher than 30µM we found that our designed NB started to 
show great toxicity to cells, and we found that most cells died after incubating the beacon 
for only a few minutes, most likely due to the positive charge nature of the Tat peptide. 
Therefore, the future design must take into consideration the potential toxicity of 
positively charged cell penetrating peptides. 
In a brief summary, these results reveal the possibility of using TFB NB for 
cancer cell imaging: under physiological conditions and above their CMCs, the designed 
NB molecules self-assemble into spherical micelles with the cleavable linker buried 
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within the core. Upon accumulation in the tumor microenvironment or entering the 
lysosomes, which are known to have an acidic environment, the NBs can be expected to 
gradually dissociate to individual molecules due to dilution or/and pH triggering, thereby 
exposing the cleavable linker to the target enzyme. Eventually, in the presence of CatB, 
5-FAM will be released and its fluorescence can be used as an indicator for the presence 
of CatB.  
2.5  Conclusion and Future Prospects  
In this work, we demonstrate a generic design of a new type of supramolecular 
nano-beacon by incorporating a fluorophore, a quencher and a hydrophilic cell 
penetrating peptide into one amphiphilic molecule. Our results clearly reveal the 
difference in CatB degradation kinetics between TFB molecules and supramolecular 
nanostructures, and demonstrate the potential for possible cancer cell imaging. However, 
there are still many challenges ahead for the development of supramolecular nanobeacons 
suitable for in vivo studies. First and foremost, the CMC value must be lowered to the 
nanomolar range for the construction of stable supramolecular beacons during the 
circulation. The CMC value of current design is around 30 µM, and our cytotoxicity 
studies have shown that it is not possible to maintain such a high concentration in plasma 
due to the toxicity of the Tat peptide. Second, a greater challenge is the controlled 
dissociation of supramolecular beacons into monomeric form. New features must be 
included in the future design such that once the supramolecular nano-beacons reach the 
targeted sites they could undergo a specific transition into monomeric form. The dilution 
and pH triggering mechanisms of the current system, although suitable for imaging 
purposes, could present a limitation or hurdle for quantification of enzymatic activities. 
 
 38 
Third, other important parameters must also be considered, including the emission range 
of the used fluorescent dye (near infrared region is preferred for in vivo studies), the 
potential effects of pH and ionic strengths on the fluorescence intensity, cellular uptake 
mechanisms associated with different cell types, the rate-limiting steps in the cleavage 
reactions, and the inclusion of another type of molecular probes of different modalities 
(MRI, or PET) for deep tissue tracking. Despite these intimidating challenges, we believe 
that the facile tunability of supramolecular nanomaterials in size, shape and surface 
chemistry offers new opportunities for the development of enzyme sensors for the 
imaging and diagnosis of cancer cells. 
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3 Shape- and Charge-Dependent Cellular 
Internalization of Self-Assembling 




3.1  Abstract 
Intracellular sensing of pathologically relevant biomolecules could provide 
essential information for accurate evaluation of disease staging and progression, yet the 
poor cellular uptake of most water soluble molecular probes limits their use as effective 
protease sensors. Rational design of molecular probes capable of self-assembling into 
supramolecular nanoprobes presents a potential strategy to alter their interaction 
mechanisms with cells thus promoting their effective cellular entry and intracellular 
accumulation. Herein we report on the design and synthesis of both peptide-based 
molecular beacons that could spontaneously associate into either spherical or cylindrical 
supramolecular protease sensors, depending upon their growth kinetics and assembly 
conditions. Our confocal imaging and flow cytometry results suggest that cancer cells 
had difficulties internalizing negatively charged monomeric molecular beacon and also 
those with extremely high-aspect-ratio cylindrical nanobeacons regardless of their charge 
status, but could rapidly internalize positively charged spherical nanobeacons. These 
studies corroborate the shape-dependent cellular uptake of filamentous nanostructures 
and the charge-dependent internalization of spherical nanoparticles, and more importantly 
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provide insight into the rational design of supramolecular nanoprobes with regulated 
cellular uptake characteristics by tuning their physicochemical properties. 
3.2  Introduction 
 Molecular imaging has shown great potential in various applications such as drug-
development, cancer early detection and cancer patient prognosis.
118-120 
This emerging 
technology enables us to characterize and evaluate biological processes at subcellular and 
molecular level by visualizing or quantifying the signal that originates from interactions 
between biomolecules and molecular probes.
121,122
Molecular probe serves as the 
reporting agent that translates biological information regarding disease stages or tumor 
location into measurable signals, often possessing unique imaging modality such as 
positron emission tomography (PET), optical fluorescence, and magnetic resonance 
imaging (MRI).
121-123 
To obtain explicit and reliable diagnostic information, desirable 
characteristics of an ideal molecular probe include high signal-to-noise ratio to discern 
cancer cells from normal tissue, high affinity to preferentially accumulate in target sites, 
high specificity and high sensitivity in detecting particular biomarkers, and high stability 
in in vitro and in vivo conditions to reduce chances of proteases degradation.
121-124 
Due to 
their hydrophilic nature, one particular challenge in the use of water-soluble molecular 
probes for intracellular sensing is their effective cellular uptake into cells of interest, thus 
resulting in lower specificity and sensitivity to detect cancer cells. One effective approach 
to enhance cellular uptake is to covalently incorporate into the design a small auxiliary 
segment such as cell-penetrating peptide (CPPs)
125 
and receptor targeting ligands.
126,127 
However, the resulting conjugates are still water soluble which may suffer from 
premature degradation. To overcome this hurdle, we devised the molecular probe with 
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hydrophobic segment to regulate cellular internalization as well as incorporating an 
amyloid-forming peptide sequence to induce the formation of supramolecular 
nanoprobes.  
Our ultimate interest lies in the regulation of the cellular uptake of nanoprobes via 
modulating their physicochemical properties. Various studies have reported that 
nanoparticle size and shape can affect both their internalization efficiency and 
endocytosis pathway
128-130
 due to the differences in size-dependent membrane wrapping 
time and the size limitation of certain endocytosis pathways.
131,132 
For example, Discher 
and coworkers found that polymeric spheres and filomicelles in micrometer range were 
taken up by phagocytes more easily than longer filaments
133
; DeSimone’s group  used 
poly(ethylene glycol) hydrogel to make various nanoparticles and showed that HeLa cells 
internalized cylindrical particles faster than spherical ones
134
; using gold and silver 
nanoparticles coated with antibody, Chan and coworkers found that cellular binding and 
subsequent cellular response is strongly mediated by nanoparticle size
135
; while 
Mitragotri’s group demonstrated higher cellular specificity for antibody-coated nanorods 
than their spherical polystyrene counterpart.
136 
These vital studies revealed the 
importance of nanoparticle’s size, shape and charge in cellular interactions; however, 
very few reports have investigated the interdependency of two or more parameters of 
nanoparticles in one single system. Therefore, a system with tunable properties that could 
closely mimic nanocarriers used in biomedical areas is needed to elucidate the interaction 
between nanocarriers and cells.  
Our approach is to design self-assembling molecular probes by incorporating a 
hydrophobic fluorescence detection moiety into a self-assembling peptide domain with 
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tunable hydrophilic terminus. This concept has been used to construct peptide 
amphiphiles
69,137-140
 and other peptide-based self-assembling units,
141,142 
which offers a 
feasible way to prepare nanostructures with different well-controllable properties by 
carefully tuning both the hydrophobic block and hydrophilic peptide sequence.
143-145 
In 
this study, we synthesized two conjugates that differ only in their terminal residues: one 
is positively charged and the other one is negatively charged. These molecules of 
different charges can self-assemble into spherical or cylindrical micelles when prepared 
through different kinetic pathways. Noteworthy, we also included the beacon concept
99
 
into our design by introducing the 5-FAM and Black Hole Quencher-1 pair into the 
conjugates which will only fluoresces upon cathepsin B enzyme degradation after cellular 
entry, allowing us to exclude any false positive signals arising from the cell membrane 
absorption. Our results showed that positively-charged spherical nanoprobes were 
internalized ~3-fold higher than its soluble molecular probe counterpart which underlines 
the distinction between nano- and molecular system. 
3.3  Experimental Procedures 
3.3.1 Self-assembly of Spherical and Cylindrical Nanostructures/Nanobeacons  
HFIP, known to break amyloid-beta interaction into homogenous monomeric 
form, was used in this sample preparation procedure.  SFB-K and SFB-E molecules were 
first dissolved in HFIP and the concentration was calibrated to 200 µM in 200 μL HFIP 
(hexafluoroisopropanol). For SFB-KE, 100 μL of each SFB-K (200 μM) and SFB-E (200 
μM) HFIP solutions were mixed to achieve molecular level mixing at 1:1 equimolar ratio. 
All sample SFB-K, SFB-E and SFB-KE in 200 µM and 200 μL HFIP were prepared in 
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glass vials. HFIP was then removed using a rotary evaporator, in a 40 
o
C water bath for 
10 minutes, leaving a thin film of dry nanobeacons on the wall of the glass vial. 
For the monomers preparation, all samples were reconstituted in 200 µL of 
DMSO and kept at room temperature. For the spherical nanostructure formation, all 
samples were reconstituted in 50 μL 100 mM HEPES buffer and 150 µL of water was 
added to yield a final sample concentration of 200 μM in 25 mM of HEPES buffer and all 
samples were kept in 4 
o
C. 
In the cylindrical nanostructure preparation, SFB-K and SFB-KE were dissolved 
in 50 μL 100 mM HEPES buffer and 150 µL of water was added to yield a final sample 
concentration of 200 μM in 25 mM of HEPES buffer. These samples were sonicated in a 
water bath for 20 minutes and kept at room temperature. The SFB-E nanobeacons were 
dissolved in 1xDPBS solution to yield a final concentration of 200 µM and were stored at 
room temperature.  
All monomers, spherical and cylindrical samples were pre-treated with HFIP 
except the cylindrical SFB-E sample, which was dissolved directly in 1xDPBS from its 
lyophilized powder form.   
3.3.2  Transmission Electron Microscopy (TEM) and Cryo-TEM 
Spherical nanostructures (SFB-K, SFB-E and SFB-KE) were aged for 1 day in 4 
o
C and cylindrical samples were aged for >4 days at room temperature; 5 μL of sample 
was spotted on a carbon film copper grid with 400 square mesh (from EMS: Electron 
Microscopy Sciences) and the excess was removed with filter paper to leave a thin film 
of sample on the grid. After letting the sample dry for 10 minutes, 5 µL of 2% uranyl 
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acetate was added to sample grid, and the excess was removed after 10 seconds. All 
samples were dried for at least 2 hours before TEM imaging.  
Cryogenic TEM imaging was also performed on the FEI Tecnai 12 TWIN 
Transmission Electron Microscope, operating at 80 kV. 3-5 µL of sample solution were 
placed on a holey carbon film supported on a TEM copper grid (Electron Microscopy 
Services, Hatfield, PA). All the TEM grids used for cryo-TEM imaging were treated with 
plasma air to render the lacey carbon film hydrophilic. A thin film of the sample solution 
was produced using the Vitrobot with a controlled humidity chamber (FEI). After loading 
of the sample solution, the lacey carbon grid was blotted using preset parameters and 
plunged instantly into a liquid ethane reservoir precooled by liquid nitrogen. The vitrified 
samples were then transferred to a cryo-holder and cryo-transfer stage which was cooled 
by liquid nitrogen. To prevent sublimation of vitreous water, the cryo-holder temperature 
was maintained below -170 °C during the imaging process. All images were recorded by 
a SIS Megaview III wide-angle CCD camera.  
3.3.3 Zeta Potential Measurement 
Zeta-potential measurements were carried out using Malvern Zetasizer Nano 
instrument and its compatible disposable capillary cell (DTS 1070 from Malvern). 
Spherical and cylindrical SFB nanobeacons were instantly diluted from 200 µM to 5 μM 
in water with a final volume of 1 mL. Measurements were carried out in automated mode 
and repeated three times to obtain an average value and its standard deviation. 
3.3.4 Activation of Nanobeacon with Cathepsin B Enzyme 
CatB enzymatic reaction buffer was prepared in 50 mM sodium acetate buffer 
with 25 mM L-cystein as enzyme activator and 1 mM EDTA was added as enzyme 
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stabilizer. 0.1 Unit of CatB was pre-incubated in reaction buffer for 5 minutes at 37 
o
C to 
activate the enzyme and SFB nanobeacons were added to reaction buffer to yield a final 
concentration of 5 μM and final volume of 100 μL.  All samples were triplicated and the 
experiment was carried out in a 96-well standard opaque plate. 5-FAM molecule was 
excited at 492 nm and emission was collected at 520 nm with 515 nm cut off. Using a 
Gemini XPS microplate reader (Molecular Devices, Sunnyvale, CA), the kinetic mode 
was selected and fluorescence intensity was measured for 125 minutes with fluorescence 
readings at 5 minute intervals. 
3.3.5 In vitro Cellular Uptake and Inhibition Protocol 
PC3-Flu cells were seeded onto 24-well plate with cell density of 1x10
5
 cells/well 
and incubated in 37 
o
C, 5% CO2 overnight. 5 µM of SFB nanobeacons (monomers, 
spherical and cylindrical, independently) was prepared by adding 12.5 μL of 200 µM 
SFB stock solution into 487.5 μL of 1640 cell medium for PC3-Flu. PC3-Flu cells were 
incubated with the cell medium containing 5 µM of SFB nanobeacons for 1 hour in 37 
o
C. On the other hand, the energy-dependent endocytosis was inhibited by pre-treatment 
with 10 mM sodium azide and 10 mM 2-deoxy-D-glucose for 15 minutes, followed by 5 
µM SFB nanobeacons incubation for 1 hour in 37 
o
C. Cell medium was removed and 200 
μL of Trypsin Gibco 0.25% Trypsin-EDTA (1x), phenol red (Life Technologies 
Corporation) was added to PC3-Flu cells and incubated for 2 minutes at room 
temperature. 500 µL of 1640 cell medium was added to each well and cell were re-
suspended from the bottom of each well, then transferred into 1.5 mL Eppendoff tube and 
kept in ice. All cells were centrifuged at 1.7k RPM for 90 seconds and the supernatant 
was removed. 500 μL cold 1xDPBS was added to wash cells and re-centrifuged at 1.7k 
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RPM for 90 seconds. The supernatant was removed and 200 µL of cold 1xDPBS was 
added to re-suspend cells, and then transferred into flow-cytometry tube. 10,000 of live 
cells were gated and fluorescence intensity was detected using flow-cytometer 
(FACSCalibur, BD). 
3.3.6 Confocal Laser Scanning Microscopy 
PC3-Flu were seeded onto 8-well plate with cell density of 3x10
4
 cells/well and 
incubated overnight in 37 
o
C incubator. 7.5 μL of 200 µM SFB nanobeacons were added 
to 292.5 μL of 1640 cell medium and transferred to each well containing PC3-Flu cells. 
The cells were kept in 37 
o
C for 1 hour and then the medium was removed, followed by a 
quick wash with 300 µL of cell medium without phenyl red. PC3-Flu cells were imaged 
directly without fixing the cells. The cell nuclei were stained in blue with Hoechst 33342 
and lysosome compartments were stained with Lysotracker Red for 30 minutes before the 
cell imaging. 
3.4  Results and Discussions 
3.4.1 Molecular Design 
 Peptide-based system offers a versatile platform to rationally design a self-
assembly nanoparticles with amphiphilic property, self-assembly-driven domain and 
tunable terminus charge. To achieve desired amphiphilicity in our design, a hydrophobic 
quencher and fluorophore were conjugated to a peptide domain with hydrophilic end. 
Apart from the contribution of amphiphilicity, another governing factor to attain 
controlled self-assembled nanoparticles relies on the peptide domain that consists of 
strong hydrogen-bond forming sequence, such as Sup357-13 heptapeptide GNNQQNY.
146 
This feature allows one-dimensional cylindrical growth of molecular probes upon self-
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assembly in an explicit condition. In this study, we designed two self-assembling 
molecular beacon, namely SFB-K (Figure 3-1a) with three lysines as terminal residues 
and SFB-E (Figure 3-1a) with three glutamic acids serving as the charge source upon 
ionization of their side chains. Besides the differences in terminal residues, the two 
molecules are exactly the same and composed of four parts, consisting the amyloid-
forming peptide Sup357-13,
147
 a fluorophore with green fluorescence(5-FAM), it’s 
compatible quencher (BHQ-1) and an enzyme degradable linker (-GFLG- 
tetrapeptide)
85,148 
connecting 5-FAM to Sup35. The beacon concept utilized BHQ-1 to 
quench the 5-FAM fluorescence by their connection through an intracellular enzyme 
cleavable linker -GFLG-. In our previous work, we have proved that the breaking of this 






Figure 3-1. (a) Chemical structure of SFB-K and SFB-E nanobeacons; the terminal 
amino acids were designed to be lysine or glutamic acid, respectively. Sup35 
(GNNQQNY) was used as self-assembling peptide domain and -GFLG- tetrapeptide was 
incorporated as CatB responsive linker. (b) The self-assembly of SFB molecules were 
conducted at different temperatures to obtain spherical (cold, 4 
o






3.4.2 Molecular Self-Assembly 
 We found that spherical micelles can be formed from the same molecules through 
different kinetic pathways by controlling temperature, buffer and time of aging. In order 
to initiate self-assembly from molecular level, hexafluoroisopropanol (HFIP) was used to 
disrupt existing beta-sheet oligomers/fibrils
150,151
 formed during peptide synthesis and 
purification. SFB-K and SFB-E nanobeacons were each dissolved in HFIP to obtain a 
200 μM concentration. For SFB-KE sample preparation, SFB-K and SFB-E were mixed 
at molecular level in HFIP solution yielding 1:1 equimolar mixing ratio. All HFIP pre-
treated samples were vacuum dried using a rotary evaporator, forming a thin peptide film 
on the glass vials. For spherical SFB nanobeacons (SFB-K, SFB-E and SFB-KE) 
preparation, the peptide film was reconstituted in 25 mM HEPES buffer and stored at 4 
o
C. For cylindrical nanobeacons preparation, HFIP-pretreated/dried SFB-K and SFB-KE 
thin films were reconstituted in 25 mM HEPES buffer and sonicated for 20 mins in a 
water bath. We observed that the HFIP-pretreated/dried SFB-E formed polydispersed 
nanostructures (spherical and cylindrical) after being reconstituted in 25 mM HEPES 
buffer. Therefore, we prepared the cylindrical SFB-E by dissolving its lyophilized 
peptide power directly in 1xDPBS buffer without HFIP pre-treatment. All cylindrical 
nanobeacons samples were stored at room temperature and aged for at least 3 days to 




Figure 3-2. Regular TEM images of self-assembled spherical and cylindrical 
nanostructures formed by SFB-K (a,d), SFB-E (b,e) and SFB-KE (e,f) at 200 µM. All 
samples except cylindrical SFB-E were prepared from the HFIP pre-treated molecules 
and reconstituted in 25 mM HEPES buffer, Spherical nanostructures were kept at 4 
o
C 
while cylindrical nanostructures were aged for more than 4 days at room temperature, in 
the dark. Cylindrical SFB-E was prepared by directly dissolving the molecules in 
1×DPBS. 
3.4.3 Nanostructure Characterization 
In order to validate the self-assembled structures formed by SFB-K, SFB-E and 
SFB-KE, TEM (Transmission Electron Microscopy) and cryo-TEM techniques were used 
to determine the nanostructure’s morphology and diameter. TEM images in Fig 2(a-c) 
showed that 200 μM samples of SFB-K, SFB-E and SFB-KE formed spherical 
nanostructures of diameter 7.8 ± 0.9 nm, 7.6 ± 1.3 nm and 8.5 ± 1.0 nm, respectively. As 
shown in Figure 3-2(d-f), TEM images revealed cylindrical SFB-K, SFB-E and SFB-KE 
structures with 9.24 ± 1.9 nm, 8.86 ± 1.4 nm and 11.95 ± 1.6 nm diameters, respectively. 
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With the estimation of SFB molecule’s extended length of 7 nm, these SFB molecules 
were most likely self-assembled into a core-shell structure with hydrophobic group 
embedded and overlapped in the center.
69 
To avoid possible distortions resulting from 
negative staining in regular TEM, cryo-TEM was performed to capture images of 
cylindrical nanobeacons in their hydrated form as shown Figure S4. Both spherical and 
cylindrical nanobeacons were stable and were able to maintain their self-assembled 
nanostructures throughout the course of the studies (Figure S7).  
 To characterize the surface charge of these designed nanostructures, zeta-potential 
measurements were conducted for each of the samples. As expected, SFB-K with free 
amines on the lysine side chains resulted in a positive zeta potential of +40.7 ± 2.1 mV 
and +42.9 ± 0.7 mV for spherical and cylindrical nanostructures, respectively. On the 
other hand, the negative surface charge of SFB-E nanostructures was contributed by the 
free carboxylic group of glutamic acid’s side chain and the C-terminus when they were 
deprotonated. The zeta potentials for spherical and cylindrical SFB-E were -50.2 ± 1.6 
mV and -61.1 ± 6.2 mV, respectively. In a 1:1 mixing ratio of SFB-K and SFB-E, SFB-
KE showed negative surface charge of -30.8 ± 1.1 mV and -40.4 ± 3.6 mV for spherical 
and cylindrical nanostructures, respectively. When dissolved in 50mM HEPES buffer that 
has pH 7.0, both the side chain of Lys (pKa=10) and Glu (pKa=4) as well as the C-
terminus of Glu (pKa=2) will be fully ionized. Therefore, the anionic characteristic of 
SFB-KE nanostructure was a result of an overall negative charge upon mixing of SFB-K 
with three free amine groups and SFB-E with three side chain carboxylic acids and one 
terminal carboxylic acid group.   The nature of our designed molecule self-assembling 
into different shapes with different surface charges offers an interesting system that can 
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be utilized to study the effect of shape and surface charge of nanostructures on cellular 
uptake. The successful preparation of spherical and cylindrical nanobeacons using the 
same molecules provides nanostructures that only differ in their shape or surface charge, 
which allows us to understand the role of the individual parameters or their interplay in 
the cellular entry process. 
3.4.4 Cellular Uptake of Nanobeacons 
 The cellular internalization of the self-assembled nanostructures was investigated 
using PC3-Flu, a metastatic human prostate cancer cell line, which showed increased 
expression of CatB due to its aggressiveness.
152-157 
The pre-seeded cells were treated with 
complete medium containing 5 μM of SFB nanobeacons of respective charge and shape 
for 1 hour. To exclude the possibility of self-assembled nanostructures dissociating into 
their monomeric form during experimental condition, SFB monomers were prepared in 
DMSO and were included in the in vitro cell study as a control set. The internalization 
rate of SFB nanobeacons was evaluated by quantifying the released 5-FAM fluorescence 
through the flow cytometry method, because the SFB can be cleaved to release 5-FAM 
after their encounter with CatB regardless of their morphology and surface charge (Figure 
S6). Noteworthy, the intracellular concentration of CatB is much higher
158 
than the 
concentration used in our enzymatic degradation experiments (3000 mU versus 25 mU 
per 1 μM of SFB), therefore the difference in cleavage rate of conjugates in different 




Figure 3-3. PC3-Flu cells were incubated with 5 µM of SFB nanobeacons for 1 hour and 
the cellular uptake rate of nanobeacons were compared by measuring each cell’s 
fluorescence intensity. (a) Fluorescence intensity obtained from flow-cytometry showed 
spherical SFB-K internalized faster than SFB-K monomers and cylindrical state. Upon 
inhibition of energy-dependent endocytosis pathway, +i (dashed bar), PC3-Flu cells did 
not show appreciable uptake of SFB nanobeacons. (b) Flow cytometry spectra comparing 
fluorescence intensity of different shapes of SFB-K, SFB-E and SFB-KE. All the data 
was presented as mean ± s.d. (n = 3). 
3.4.5 Shape Effect 
 From flow-cytometry results, we observed significant difference in the cellular 
uptake of spherical nanobeacons than its counterparts. PC3-Flu cells incubated with SFB-
K spherical nanobeacons showed ~3 fold fluorescence increase than monomeric 
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nanobeacons and ~ 7 fold increase than cylindrical nanobeacons, as shown in Figure 3-
3a. When comparing monomeric and cylindrical nanobeacons, flow-cytometry showed 
approximately 2 fold increase in monomers cellular uptake than cylindrical nanobeacons, 
as shown by the red and blue bars of Figure 3-3a. These results support the stability of the 
self-assembled nanostructure we attested to earlier (Figure S7d-e), clearly indicating that 
the cylindrical micelles were stable throughout the experimental period of 1 hour in 37 
o
C. Through TEM characterization, however, it is more challenging to prove the stability 
of spherical micelles in complete medium due to the existing globular protein, such as 
human serum albumin, HSA (Figure S8). Using a biological relevant buffer (1xDPBS), 
we showed that spherical nanobeacons maintained their self-assembled state under 
experimental condition (Figure S7a-c). Moreover, the huge difference between cellular 
uptake of SFB-K in its monomer and spherical micelle form strongly suggests the 
stability of spherical micelles in cell culture medium. Therefore, we conclude that the 
observed differences in cellular uptake arise from their differences in self-assembled 
state. When comparing the intracellular accumulation of nanostructures with different 
shapes, we found that the spherical micelles outperformed cylindrical micelles regardless 
of their surface charge, which is in consistence with previous reports.
128 
 
3.4.6 Charge Effect 
 In terms of charge effect, cellular uptake of nanocarriers was known to be 
regulated by the surface chemistry, with the cationic nanoparticles showing higher 
intracellular accumulation.
159 
We observed similar trend from our results where cationic 
SFB nanobeacons were internalized faster than SFB-E and SFB-KE which were 
negatively charged (Figure 3-3a). This phenomenon is most likely caused by the 
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electrostatic interaction of cationic nanoparticles with a slightly anionic cell 
membrane.
159,160 
More importantly, aside from these general observations, we found that 
only the cellular uptake of spherical nanoparticles is greatly affected by their surface 
charge: spherical cationic nanoparticles fluoresced in cells more than 6 times higher than 
anionic spheres did. Overall, cylindrical nanobeacons did not show significant uptake 
regardless of its surface charge. We speculated that the elongated cylindrical 
nanostructures in micro-meter length were too long for the cells to take in. Through this 
experiment, we observed an interdependent relationship between the shape and surface 
charge of nanostructure in order to achieve optimized cellular uptake.  
3.4.7 Energy-dependent Endocytosis Inhibition 
 There have been several reports showing that nanoparticles with positive surface 
chemistry can directly penetrate across cell membranes without creating any toxicity to 
the cells.
161 
To better comprehend the greater intracellular accumulation of cationic 
spherical nanobeacons, we assessed their endocytotic pathway and ability to penetrate 
cells directly. We compared the cellular uptake of nanocarriers and monomers by PC3-
Flu cells with or without treatment with 10 mM sodium azide (NaN3) and 10 mM 2-
deoxy-D-glucose (DDG), the combination of which proved to inhibit the energy 
production efficiently.
162 
PC3-Flu cells were pre-incubated with 10 mM NaN3 and 10 
mM DDG for 15 minutes, and then they were incubated with 5 µM SFB nanobeacons for 
1 hour in 37 
o
C. The result in Figure 3-3a showed that the cellular uptake of all the 
formulations was inhibited to a basal level (shaded bars, <10%), clearly indicating that 
the cellular uptake of conjugates followed the energy-dependent endocytosis pathway 




Figure 3-4. Confocal laser scanning microscopy of PC3-Flu cells after 1 hour of 
incubation with 5 µM of SFB nanobeacons in different shapes and charges. (a-c) 
Monomers of SFB-K, SFB-E and SFB-KE, respectively; (d-f) spherical nanobeacons of 
SFB-K, SFB-E and SFB-KE, respective ely; (g-i) cylindrical nanobeacons of SFB-K, 
SFB-E and SFB-KE, respectively. Scale bar: 20 µm. 
3.4.7 Cancer Cell Imaging 
 Since the flow cytometer cannot differentiate whether the fluorescence originates 
from inside of the cells or on the cell membrane, the cellular uptake of different 
nanocarriers was further determined by confocal microscopy. This technique allowed us 
to visually observe the location of fluorescence in cell, thereby justifying our collected 
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data was solely based on internalized nanobeacons and not false signals generated from 
premature degradation of beacon molecules outside of the cells. PC3-Flu cell nuclei were 
stained in blue using Hoechst 33342 and the released 5-FAM from the SFB nanobeacons 
fluoresced in green. The images in Figure 3-4 clearly showed that all the fluorescence 
was located inside the cells, and the strongest fluorescence was observed from the cells 
treated with positively charged spherical micelles (Figure 3-4d). It was reported that the 
positively charged particles can induce the formation of a temporary transmembrane 
pore, which is associated with its toxicity.
163-165 
It is possible that higher intracellular 
accumulation of positively charged nanoparticles is a result of its toxicity to the cells. 
However, this possibility can be excluded since we did not observe any significant 
change in viability of cells treated by conjugates of different morphology and surface 




Figure 3-5. Confocal microscopy images of (a) released 5-FAM (green) and (b) 
Lysotracker Red staining lysosome (red) of PC3-Flu cells after incubation with 5 μM of 
spherical SFB-K for 1 hour. (c) Overlay of green and red channels showed co-
localization of released 5-FAM in lysosome. (d-e) Colocalization of green and red 
channels was quantified and the weighted colocalization coefficient was determined to be 
86.5 ± 8.4% (n = 20 cells). 
Since the positively charged spherical nanoparticles showed the highest 
intracellular accumulation, nanocarriers with the same properties are of great interest to 
design intracellular sensing probe. Besides the intracellular accumulation, the subcellular 
distribution of nanoparticle has also proven to be critical for potential biomedical 
applications.
166,167 
To better comprehend the internalization of the spherical SFB-K 
nanoparticles, PC3-Flu cells were pre-treated with Lysotracker Red to label the lysosomal 
compartments in the cells. The merged image of 5-FAM green fluorescence (Figure 3-5a) 
and lysotracker red (Figure 3-5b), showed in yellow (Figure 3-5c), indicated the co-
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localization of 5-FAM in the lysosome. The fluorescence intensity of 5-FAM and 
lysotracker red across PC3-Flu cell was quantified in Figure 3-5d-e  and the 
colocalization coefficient coefficient was determined to be 86.5 ± 8.4%, which indicated 
high correlation of 5-FAM in the lysosomal compartment.
168 
Therefore, if cytosolic or 
other organelle, deposition of enzyme-susceptible-molecule is required, a lysosome 
escape mechanism or organelle targeting moiety should be incorporated into the 
nanobeacon design for future applications. 
3.5  Conclusion  
 In this study, we showed that the self-assembly of SFB nanobeacons were tunable 
into different shapes, such as spherical and cylindrical, as well as presenting different 
surface charges based on the peptide design sequence. The SFB nanobeacons were 
activatable by the degradation cathepsin B enzyme, releasing 5-FAM for fluorescence 
detection. In vitro studies showed a higher cellular uptake rate for spherical SFB than its 
counterparts - monomers and cylindrical nanobeacons. Also, the nanostructure’s surface 
charges showed distinct effect in cellular uptake rate where cationic nanobeacons were 
internalized faster than catanionic mixture and anionic nanobeacons.  
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4 Enzyme-specific doxorubicin drug beacon as 




We report here on the use of anticancer drug doxorubicin (Dox) to construct a FRET-
based theranostic molecular probe by covalently linking together through a lysine 
junction a fluorescent drug, a black hole quencher, and a cell penetrating peptide. We 
show that upon cleavage by the target lysosomal protease cathepsin B (CatB), the 
designed drug beacon could release the fluorescent drug serving as an indicator for CatB.  
Our cell studies suggest that the drug beacon design can help to circumvent the Dox drug 
resistance in NCI/ADR-Res ovarian cancer cells, showing significant improvement in 
cell cytotoxicity compared to the free drug. We believe our design opens up new 
opportunities to exploit the new functional and structural features of anticancer drugs in 
addition to their characteristic cytotoxicity. 
4.2 Introduction 
    Proteases are known to play a critical role in the development and progression of 
many human diseases such as cancer.
35,169,170 
Accordingly, a number of oncological 
treatments have targeted the over-expression and abnormal activities of cancer-relevant 
proteases for on-site release of drugs,
171-173 
 enzyme-responsive diagnostic agents,
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as well as the development of protease 
inhibitor drugs.
175 
One particular application has been the creation of polymer-drug and 
peptide-drug conjugates through an enzymatically activatable linker to improve the tumor 
targeting efficiency and to circumvent multidrug resistance mechanisms.
148,173,176-179 
 In 
such a prodrug design, the release rate and location of the conjugated drug is primarily 
determined by the enzymatic activities of the protease of interest. Therefore, in 
conjunction with the development of novel molecular imaging agents for cancer detection 
and prognosis, great effort has been devoted to the design of activatable molecular probes 
for sensing protease activities.
2,149,180-183  
For example, Chen and co-workers reported the 
design of protease-activatable probes for matrix metalloproteinases detection.
184 
The 
activation mechanism for these optical probes is primarily based upon a change in Förster 
resonance energy transfer (FRET) between a pair of fluorescing reporter and quencher 
moieties before and after the enzymatic degradation. In this communication, we report 
the design, synthesis and in vitro evaluation of a doxorubicin (Dox) drug-beacon system, 
which to the best of our knowledge, is the first enzyme-specific Dox prodrug conjugated 
with a dark chromophore quencher, possessing both therapeutic and diagnostic functions. 
The designed Dox drug-beacon was also found to circumvent the drug-resistant 
mechanism in NCI/ADR-Res ovarian cancer cells and induce higher cytotoxicity relative 
to the free Dox. 
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4.3 Results and Discussions 
4.3.1 Molecule Design 
 
Figure 4-1. a) Chemical structure of the designed R8DB drug beacon with octa-arginine 
sequence (purple), -GFLG-linker (green), Dox (red) and BHQ-2 (black). b) Schematic 
illustration of R8DB activation from off-state to on-state after cathepsin B degradation. 
The designed Dox drug-beacon is expected to remain dark (OFF-state) prior to cellular 
entry. Following cellular uptake and CatB cleavage of the –GFLG-linker, Dox will be 
released thus emitting fluorescence while acting as a therapeutic agent (ON-state).   
Figure 4-1 shows the chemical structure and the expected activation mechanism 
of the designed Dox drug-beacon (R8DB) containing four major components. First, the 
anticancer drug Dox, the reporter moiety, is an anthracycline antibiotic that has been 
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widely used as a chemotherapeutic drug for various cancer treatments,
185 
emitting a red 
fluorescence in the range of 560–590 nm when excited at 480 nm. Second, Black Hole 
Quencher-2 (BHQ-2) was chosen as the acceptor/quencher moiety due to its strong and 
broad absorbance from 500 nm to 650 nm. Its pairing with Dox is expected to effectively 
quench the Dox fluorescence through the FRET mechanism due to its absorption overlap 
with the Dox emission. Upon excitation, BHQ-2 preferentially relaxes to the ground state 
through non-radiative processes instead of generating new photons, thereby offering a 
high signal-to-noise ratio. This FRET-based concept has been extensively used to 
construct molecular beacons for sensing of DNA, RNA and other biomolecules.
186-189 
 
Third, the tetrapeptide -GFLG-, a well-established cathepsin B (CatB) substrate
85,148
 was 
used as the cleavable linker to bridge the drug to the BHQ-2 quencher through a lysine 
junction, modulating the release of Dox while serving as a CatB sensor. Cathepsin B is a 
lysosomal protease known to be overexpressed in many types of cancer.
155,190-194 
 Finally, 
octa-arginine (R8), a well-studied cell penetrating peptide (CPP) sequence,
195 
was used to 
assist in the effective cellular internalization.
196 
All the molecules studied here were 
synthesized using a combined automatic and manual solid phase peptide synthesis 
(SPPS) method as reported previously.
149 
After HPLC purification, analytical HPLC and 
Mass Spectrometry were used to confirm the purity and expected molecular mass for the 
synthesized compounds. Their details can be found in Electronic supporting information 






4.3.2 Quenching Effect and Enzymatic Activation 
 
Figure 4-2. a) Fluorescence emission spectra of free Dox (black line) and R8DB (red 
line) at 3µM. b) Fluorescence emission spectra of a 3 µM R8DB solution at different time 
points after introducing 0.05 U of CatB. c) Changes in fluorescence intensity of a 3 µM 
R8DB solution in the presence of various amounts of CatB: 0.00 U (Black), 0.005 U 
(Blue), 0.01 U (Green) and 0.03 U (Red). d) Plot of initial cleavage rates (obtained from 
time 0-30 minutes of (c)) shows a linear correlation with the CatB concentration. 
We first determined the quenching efficiency of BHQ-2 after its conjugation onto 
the Dox beacon. In this fluorescence experiment, we excited the R8DB solution (3µM in 
1xPBS) at 465nm and collected the emission spectra as shown in Figure 4-2a, with the 
free Dox of the same molar concentration as control. The quenching efficiency was 
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calculated to be 90.6±1.6%, equivalent to a 10 fold decrease in Dox fluorescence 
intensity after incorporating the BHQ-2 quencher. Next, in an effort to demonstrate the 
enzyme-responsive feature of the R8DB drug-beacon and its possible use for CatB 
sensing, we studied their activation in a CatB-containing solution and measured their 
emission spectra at different time points. The fluorescence intensity of a 3 µM R8DB 
drug-beacon aqueous solution was observed to increase gradually after exposure to 0.05 
Units (U) of CatB enzyme for 80 minutes, exhibiting the typical emission spectrum of 
free Dox (Figure 4-2b). According to the work by Kopecek and coworkers,
85
CatB was 
reported to cleave GFLG linker at the amide bond of F and L, as well as  at the C-
terminal of GFLG. Therefore, two amino acid residues could be possibly attached to Dox 
(Dox-GL) upon initial cleavage which could undergo further degradation to release free 
Dox over time.
197 
To evaluate the Dox release profiles, we monitored the change in Dox 
fluorescence intensity over time in the presence of varying concentrations of CatB 
(Figure 4-2c). We observed that the R8DB solution without CatB showed a minimum 
level of Dox fluorescence throughout the course of study (OFF-state), while solutions 
containing 0.005 U, 0.01 U and 0.03 U of Cat B exhibited a rapid increase in Dox 
fluorescence (ON-state), commensurate with the amount of CatB used. The initial 
cleavage rates were obtained from the slope between t = 0 and t = 30 min, and found to 
scale linearly with the CatB concentration (Figure 4-2d). The kcat/KM value was 




 using the simplified Michaelis-Menten equation (S2 
in ESI). This number is four times as high as our previous finding in a different molecular 
beacon system
149
, and is in the same order of magnitude with other systems using the 
same peptide substrate.
148 
This implies that the drug beacon design does not compromise 
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the cleavage specificity of the GFLG substrate by CatB. These results also clearly suggest 
that R8DB drug-beacon can be specifically activated by the CatB enzyme, recovering the 
drug’s native fluorescence for intracellular tracking and/or CatB sensing. 
4.3.3 In vitro Cell Study 
 
Figure 4-3. Live cell confocal images of NCI/ADR-Res drug-resistant ovarian cancer a) 
without any drug (blank), b) in the presence of 3 µM free Dox and c) in the presence of 3 
µM R8DB incubated for 96 hours. Dox fluoresced in red, and lysosomal compartments 
were stained with Lysotracker Green and cell nuclei were stained in blue with Hoechst 
33342. 
We further evaluated the theranostic feature of the R8DB drug beacon in drug 
resistant ovarian cancer cell lines. It is well known that Dox is transported into cells 
through a passive diffusion mechanism, and subsequently accumulates in the cell nucleus 
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whereupon intercalation with DNA occurs to induce cell apoptosis. However, drug-
resistant cell lines could have evolved with a defensive system known as P-glycoprotein 
efflux pump to avoid accumulation of drug above its cytotoxic threshold.
198
 For a better 
comparison of drug internalization and efficacy, we incubated 3 µM of Dox and R8DB 
drug-beacon, respectively, in the drug-resistant NCI/ADR-Res ovarian cancer cell line, 
followed by fluorescence imaging of live cells using confocal laser scanning microscopy 
(Figure 4-3).  Cells after 72 hours of incubation were replaced with fresh media 
containing either the drug or R8DB drug beacon due to the depletion of nutrition. As 
shown in Figure 4-3, it is evident that R8DB drug-beacon (Figure 4-3c) exhibits much 
stronger red fluorescence in cells than the free Dox (Figure 4-3b), indicating both 
effective cellular internalization and CatB activation. This phenomenon has also been 
observed in other prodrug designs possessing CPP features that interact with drug-
resistant cell lines.
199-201 
A few studies have showed that the azo moiety in BHQs 
quencher is susceptible to reduction reaction which could possibly give rise to false 
fluorescence increase.
202,203 
However, we have previously shown that under similar 
experimental condition BHQ was able to quench and maintained fluorescence of our 
designed molecular beacon in the presence of CatB inhibitor which is known to suppress 
CatB’s activity in cleaving the GFLG substrate.
149 
To validate the subcellular 
colocalization of the R8DB drug-beacon, we selectively stained the lysosomal 
compartments with LysoTracker Green. As shown in Figure 4-3c, the red fluorescence 
coming from the released Dox was mostly located within the lysosomal compartments as 
they co-localized with Lysotracker Green. This observation confirms our assumption that 




In addition, we have attempted to trace the intracellular Dox localization for longer 
periods of time, however, cell conditions were severely deteriorated (cells started to die), 
preventing more detailed analysis of the intracellular trafficking pathways of Dox beacon. 
In Fig. 2b, the negligible red fluorescence suggests that free Dox entering cells through 
diffusion is likely pumped out by the cell drug resistance mechanism.
208,209 
 Therefore, 
the enhanced accumulation of released Dox in drug resistant cancer cells means that 
R8DB drug beacon could possibly help circumvent the drug-resistance mechanism that 
many cancer cells could develop over the course of chemotherapy. It should be noted that 
although the R8DB drug beacon has amphiphilic character and thus the potential to 
assemble into micellar structures in aqueous solutions, the extremely low concentrations 
in all experimental conditions (3 μM) and the prolonged incubation (in days) suggest that 
R8DB would have most likely remained in its monomeric form in these studies. 
4.3.4 Drug Beacon Efficacy 
 
Figure 4-4. Cytotoxicity assay of NCI/ADR-Res cells incubated with various 
concentrations of free Dox and R8DB drug-beacon (0.3 µM to 3 µM). Data are given as 
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mean ± sd (n = 3). Fresh cell media with respective drugs were used to replace the cell 
media after 3 days and the cells were further incubated for another 3 days. **P<0.001. 
   To validate the in vitro efficacy of the Dox drug-beacon design, a dose–
response study was conducted using an SRB assay (Figure 4-4), using free Dox as 
control. As expected, free Dox did not exhibit any toxicity after 6 days of incubation for 
any of the studied concentrations (0.3 µM to 3 µM, blue bars in Figure 4-4). At lower 
concentrations (0.3 and 1 µM), the R8DB drug-beacon also showed a negligible effect on 
cell viability (red bars in Figure 4-4). Although the octa-arginine peptide was known to 
facilitate the effective internalization of R8DB, the released Dox within cell could still be 
lower than the toxicity concentration threshold. At 3 µM, the R8DB drug-beacon 
exhibited remarkable improvement in drug-efficacy with only ~30% of cells remaining 
viable. This observation is consistent with our confocal imaging study, where R8DB 
showed higher Dox fluorescence intensity in cells compared to free Dox of the same 
concentration. Since octa-arginine is a highly positively charged peptide, it could 
potentially disrupt cell membranes thus causing cytotoxicity.
210 
As a result, R8DB 
concentration was deliberately set below 5 µM, a condition where the R8 peptide 
sequence was known to show negligible cytotoxicity.
211 
Therefore, our cytotoxicity result 
reflects the drug beacon’s ability to overcome the drug-resistance mechanism in 
NCI/ADR-Res ovarian cancer cells.  
4.4 Conclusion 
  In summary, we have reported a novel design of an enzyme-specific theranostic 
probe by taking advantage of the fluorescence capacity of the anticancer drug Dox. 
Incorporating a fluorescing drug into the beacon design opens up a new platform to 
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explore the diagnostic functionality of therapeutic agents. This synergistic effect could 
potentially reduce the discrepancy between tumor diagnostic locations with actual drug-
delivered sites, which is one of the important challenges in current treatment paradigm. 
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5 Self-assembling Drug-Peptide Nanofiber 
Hydrogel with Inherent MRI Signal
§
 
5.1  Abstract 
 Small molecule anticancer drug remains one of the major components in 
chemotherapy regimes. However, each anticancer drug will have unique 
pharmacokinetics profile due to tumor variation in patients, resulting in unpredictable 
therapeutic outcome. More importantly, treatment failures could not be addressed 
appropriately because of limited resources and technologies to track anticancer drug in 
real time. Here we report a proof-of-concept design and utilization of anticancer drugs 
with exchanging protons, to generate chemical exchange saturation transfer (CEST) MRI 
signal under specific radio frequency, enabling real-time report of drug distribution. The 
incorporation of self-assembling peptide offers structural advantage by promoting 
nanofibers hydrogel formation. Our results showed that Pemetrexed (Alimta) anticancer 
drug has intrinsic CEST signal at 5.4 ppm and in vivo study revealed that this approach 
was able to detect drug distribution in brain after 4 days of local injection. This strategy 
can be extended to other anticancer drug with exchanging proton, therefore presents new 
opportunities for the development of image-guided drug delivery system.  
                                                 
 
§ Lock, L.L., Li., Y., Liu, G., and Cui. H. designed the experiments. Lock, L.L. and Mao, X. performed 
peptide-drug synthesis and analyzed nanofiber data. L.Y. and L.G. performed in vitro and in vivo CEST 
experiments and analyzed the data. Bai, R. and Staedtke, V. prepared and performed the in vivo 




5.2  Introduction 
 The exploration of peptide-based nanofiber hydrogel has expanded the field of 







 and drug delivery system
220-222 
due 
to its biocompatibility, biodegradability and high tunability for different purposes. 
Similar to the notion of biomolecules assembly in Nature, the self-assembly of peptide-
based hydrogel mainly driven by a collective of weak intra- and inter-molecular 
interaction such as hydrogen bond, electrostatic, van der Waals, pi-pi stacking and 
hydrophobic interaction,
69,70,223 
forming well-defined nanofiber and further associated 
into three-dimensional hydrogel network. The ability to customize peptide sequence 
enabled to peptide hydrogel conforms to desired properties and functionality. For 
instance, charged amino acids can be incorporated into peptide design to obtain cationic 
or anionic system, various hydrophobic entities are to be modified to facilitate the self-
assembly process
224
 and most importantly, bioactive ligand can be presented on the 
nanofiber hydrogel to target a specific receptor or exhibit bio-responsive feature.
74,225 5
 A 
promising feature offered by peptide-based hydrogel is the capacity to achieve 
controlled-release of payload,
226,227 
in contrast to the burst-release profile of polymer-
based material, which has long been recognized as one of the challenges in drug delivery 
system.
228,229 
As the therapeutic efficacy of most anti-cancer drugs has been limited by 
carrier’s encapsulation capacity and efficiency as well as causing undesired side 
effects,
230 
a carrier-free self delivery system has attracted much attention. Through the 
conjugation of drug with a small molecule or short peptide that could induce the self-




Despite remarkable advancement in the development of drug delivery strategies, 
the efficacy of chemotherapeutic drugs in cancer treatment is still limited, largely due to 
the unspecific accumulation in other organs such as liver spleen, kidney;
233
 with only 
small amount of drug arriving at tumor site. Another challenge is the chemotherapeutic 
drugs were generally distributed around the peripheral of tumor owing to the high 
interstitial fluid pressure within tumor, limiting the penetration depth of drug into the 
tumor.
234
 Therefore, the ability to monitor and track therapeutic drug is highly desirable 
to identify premature clearance, locate drug accumulation site and distribution to have a 
better drug prognosis and comprehend for any treatment failures.
235
 Image-guided drug 
delivery or theranostic systems have been explored to incorporate chemotherapeutic 









 to render real time reporting of drug circulation and distribution upon in vivo 
administration.  
A newly explored MRI imaging technique, Chemical Exchange Saturation 
Transfer (CEST), utilizes the unique chemical shift (frequency offset) of exchangeable 
protons on each probe, translating them into a frequency-specific agent for molecular 
imaging.
242,243
 Unlike conventional MRI agents, these ‘frequency-encoded’ agents offer 
several advantages such as the possibility of turn the contrast ‘on’ or ‘off’ by 
manipulating the frequency offset and allowing multiple agents to be monitored at the 
same time.
244,245
 Through CEST MRI approach, bio-organic molecules
246-249
 which 
composed of exchangeable protons such as –OH, –NH and –NH2 groups can be saturated 
by a specific radiofrequency pulse and undergo rapid protons exchange with surrounding 









 with –NH proton were 
shown to exhibit CEST MRI signal that enabled in vivo microenvironment pH mapping. 
To improve the accuracy of Iopromide and Iobitridol CEST pH evaluation, ratiometric 
analysis of multiple magnetically non-equivalent protons
251
 and different radio frequency 
pulse power were developed,
253
 respectively. Recently, salicylic acid, a metabolite of 
aspirin, was reported to produce CEST contrast at 9.3 ppm downfield from water,
249
 a 
frequency that is far from endogenous tissue amine and amide signals.
247,254
 These new 
discoveries explored additional imaging functionality to existing drugs or contrast agents. 
Herein, we report an FDA-approved anticancer drug, Pemetrexed (Pem), trade 
name Alimta,
255
 with inherent CEST MRI signal at 5.4 ppm frequency offset away from 
the water signal. To achieve longer retention time at target site after local administration, 
we covalently linked Pem to a short peptide that drives the self-assembly process of Pem-
peptide conjugate forming nanofibers hydrogel. Through in vivo mouse model, we 
demonstrated that Pem can be used as a new class of CEST MRI agent and enabled real 
time monitoring of drug distribution. 
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5.3  Results and Discussions 
5.3.1 Molecular Design 
 
Figure 5-1. (a) Chemical structure of (i) Pemetrexed (Pem), (ii) FE, and (iii) PemFE 
molecules. (b) Illustration of soluble free Pem while FE and PemFE self-assembled into 
nanofibers. PemFE composed of MRI CEST signal at 5.4 ppm inherently from Pem 
molecule and 2.0 ppm from the side chain of glutamic acid as a result of closely packed 
self-assembled nanofibers state. 
 Pemetrexed (Pem) is a chemotherapeutic drug composed of aromatic amines and 
secondary amines in its nature structure (Fig. 5-1a-i). These slowly exchanging protons 
posses a chemical shift distinct from water, in which can be selectively saturated and 
transferred to bulk water through chemical exchange, resulting in a CEST signal at 
5.4ppm shift (Fig. 5-1b). With this unique property, Pem can be used as a CEST contrast 
agent. The rationale of our design is to construct a Pem-based peptide conjugate, PemFE 
(Fig. 5-1a-iii) that has the potential to self-assemble into nanofibers under physiological 
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condition. Utilizing the hydrophobic nature of most anticancer drug, we chemically 
conjugating Pem to a hydrophilic peptide (EE) to create an amphiphilic prodrug molecule 
that can self-assemble into nanostructure.
256,257 
Glutamic acid residues which carry 
negative charge at its side chain are deliberately included in our design, as other studies 
have reported that positively charge nanoparticles are prone to induce cytotoxicity.
258 
To 
promote the self-assembly of PemFE into nanofibers hydrogel, two phenylalanine (FF) 
was incorporated into the peptide sequence. The phenylalanine benzyl side chain 
composed of π-segment that was shown to direct the self-assembly of amphiphilic 
peptide into 1-dimensional nanostructures, such as nanotubes or nanofibers through π-π 
stacking.
259,260 
With this drug-peptide conjugate design, the Pem drug loading can be 
precisely fixed at 42 wt% which is defined by the mass of Pem divided by the total 
molecular weight of PemFE conjugate (Supporting information). Our previous 
work
179,256,257
 also demonstrated that this concept can be employed for other anticancer 
drugs to achieve higher drug loading compared to tradition drug encapsulation method 
which is typically below 5 wt% and drug-polymer conjugates with ~10 wt%.
55
 As a 
control molecule, we have designed the FE molecule (Fig. 5-1a-ii) which replaced the 
Pem drug with a C12-hydrocarbon tail as a hydrophobic entity to facilitate the self-
assembly process.  
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5.3.2 Self-assembly and Characterization 
 
Figure 5-2. Cryo-TEM images of (a) PemFE, 4mM  and (b) FE, 10mM showed self-
assembled nanofibers with a diameter of 9.1±1.4 nm and 8.5±0.9 nm, respectively. (c) 
Photographs of PemFE and FE in 30mM dissolved in 1xDPBS: inversion demonstrates 
self-supporting hydrogel formed by PemFE and FE self-assembling nanofibers. MRI data 
determining the CEST contrast for all molecules, PemFE, Pem, and FE. (d) Z-spectra and 
(e) MTRasym of PemFE nanofibers (green) and free Pem (red) showed CEST peak at 5.4 
ppm. (f) CEST contrast (MTRasym) map at 5.4 ppm for PemFE and free Pem. 
 The self-assembly of PemFE and FE were initiated by dissolving the lyophilized 
powder form of molecules into Dulbecco’s phosphate-buffered saline (1xDPBS). The 
self-assembled nanostructures were observed under cryogenic transmission electron 
microscopy (cryo-TEM). As shown in Figure 5-2a,c, TEM images showed that both 
PemFE and FE molecules self-assemble into cylindrical-shaped nanofibers, under 
physiological condition. According to the diameter analysis of PemFE and FE nanofibers 
obtained from the TEM images, their respectively diameter are 9.1±1.4 nm and 8.5±0.9 
nm. From the cryo-TEM images (Fig. 2b,d), the length of these nanofibers appeared to be 
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in the range of micrometer, which prone to nanofibers entanglement at high 
concentration. Consequently, at macroscopic level, PemFE and FE formed a self-
supporting hydrogel at 30mM as shown in Figure 5-2c. This hydrogel characteristic is 
highly desirable as it offers another important feature for drug-delivery system, a 
controlled-release of prodrug. 
5.3.3 In vivo CEST MRI Time-point Study and Spatial Comparison 
 To assess the potential use of PemFE hydrogel in in vivo settings, we conducted 
CEST MRI experiments on mice bearing U87 brain tumor injected with PemFE 
hydrogel. U87 mouse brain tumor cells were implanted into right hemisphere of mouse 
brain and inoculated for 25 days. Brain tumor anatomy was obtained using T2 weighted 
image to verify tumor size and location. PemFE hydrogel was administrated through 
stereotactical injection into the middle of tumor. Anatomical images and CEST map with 
respect to 5.4 ppm were collected pre-injection, 2 hours and 4 days post-injection (Figure 
5-3a). In 2 hours and 4 days PemFE hydrogel post-injection images, brain tumor resided 
at right hemisphere showed significantly higher CEST signal compared to the left 
hemisphere and pre-injection scan. After 4 days of injection, PemFE hydrogel was 
deemed to diffuse slowly to nearby tissue hence the dispersed distribution in CEST maps 
as opposed to the concentrated CEST signal at 2 hours post-injection. This study 
demonstrated that the CEST MRI feature of PemFE hydrogel is detectable in in vivo 
model and retained at injection for up to 4 days, which hold promises for extended real-
time monitor of drug release. 
 In order to attain high resolution imaging system, the CEST signal has to be 
significantly higher than background noise. To further evaluate the performance of 
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PemFE hydrogel, we quantitatively analyze the CEST MRI signal at injection site 
compared to its surrounding/background. Figure 5-3b showed an overlay image of 
CEST/MTw (magnetization transfer-weighted) using a frequency offset of 5.4 ppm, in 
which ROI1 (region of interest - ROI) sets a boundary for 2 hours post-injection of 
PemFE hydrogel and ROI2 corresponded to the surrounding/background. The CEST 
contrast of ROI1 and ROI2 (red and blue lines) were plotted in Figure 5-3c and the 
difference (gray line) was obtained by subtracting the CEST signal of ROI2 from ROI1. 
Based on the MTw image, both ROI1 and ROI2 are located within the tumor. As shown 
in Figure 5-3d, the average MTRasym values or CEST signal for the PemFE at 5.4ppm was 
higher than its surrounding. Given that the intrinsic CEST signal of Pem arises at 5.4 
ppm, it is relatively far from the possible background signal of amine and amide CEST, 
which generally spans from 2.75 pm to 3.5 ppm that accounts for amine and amide bond 
CEST signal.
247 
The larger chemical shift of Pem containing molecule (>3.5ppm) enables 
higher signal to background ratio and offers a unique identification of Pem drug in the 




Figure 5-3. MRI detection of Pemetrexed (Alimta) conjugated nanofibers hydrogel that 
was stereotactically injected in brain tumors (day 25 after tumor implantation). (a) On the 
top, MRI images showing GL261 brain tumor at different time points (with respect to the 
time of injection of nanofiber hydrogel); On the bottom, CEST maps at 5.4 ppm of the 
mouse brain before, 2 hours and 4 days after the hydrogel injection. (b) After 2 hours of 
PemFE hydrogel injection, two ROIs were manually drawn to represent the region with 
increased CEST MRI contrast at 5.4 ppm and the region in the tumor without CEST MRI 
contrast increase. (c) The MTRasym versus frequency offset plot of PemFE injected ROIs 
and their absolute difference. (d) The average of MTRasym values at 5.4 ppm comparing 
the injection site and surrounding for PemFE hydrogel after 2 hours of injection. 
 
5.4  Conclusion  
 In summary, we have demonstrated that chemotherapeutic drug, Pem can be 
utilized as a CEST agent in in vivo to monitor drug distribution over time. The CEST 
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signal at 5.4 ppm which is uniquely attributed to Pem slow-exchanging protons serves as 
a marker to identify and quantify Pem in real time. In addition, the conjugation of self-
assembling peptide to Pem drug entails the formation of nanofibers hydrogel, exhibits 
sustained-release characteristic of Pem over time. While further therapeutic evaluations 
are needed in in vivo model, our work realized the proof-of-concept in employing 
chemotherapeutic drug as a CEST contrast agent and opens up a new platform for MR 
guided drug-delivery system. The MRI capability to the drug-peptide system without 
additional burden of imaging tags conjugation could greatly facilitate the clinical 
translation.  
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6 Self-Assembly of Natural and Synthetic Drug 




6.1  Abstract 
Molecular assembly provides an effective approach to construct discrete 
supramolecular nanostructures of various sizes and shapes in a simple manner. One 
important technological application of the resulting nanostructures is their potential use 
as anticancer drug carriers to facilitate targeted delivery to tumour sites and consequently 
to improve clinical outcomes. In this carrier-assisted delivery strategy, anticancer drugs 
have been almost exclusively considered as the cargo to be carried and delivered, and 
their potential as molecular building blocks has been largely ignored. In this discussion, 
we report the use of anticancer drugs as molecular building units to create discrete 
supramolecular nanostructures that contain a high and quantitative drug loading and also 
have the potential for self-delivery. We first show the direct assembly of two amphiphilic 
drug molecules (methotrexate and folic acid) into discrete nanostructures. Our results 
reveal that folic acid exhibits rich self-assembly behaviours via Hoogsteen hydrogen 
bonding in various solvent conditions, whereas methotrexate was unable to assemble into 
any well-defined nanostructures under the same conditions, despite its similar chemical 
                                                 
 
** 
Reproduced with permission from Lock, L. L.; LaComb, M.; Schwarz, K.; Cheetham, A. G.; Lin, Y.-A.; 
Zhang, P.; Cui, H., Faraday Discussions, 2013, 166, 285-301. Copyright © 2013 Royal Society of 
Chemistry. 
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structures. Considering the low water solubility of most anticancer drugs, hydrophilic 
segments must be conjugated to the drug in order to bestow the necessary amphiphilicity. 
We have demonstrated this for camptothecin through the attachment of β-sheet-forming 
peptides with overall hydrophilicity. We found that the intermolecular interactions among 
camptothecin segments and those among β-sheet peptides act together to define the 
formation of stable one-dimensional nanostructures in dilute solutions, giving rise to 
nanotubes or nanofibers depending upon the processing conditions used. These results 
lead us to believe that self-assembly of drugs into discrete nanostructures not only offers 
an innovative way to craft self-delivering anticancer drugs, but also extends the paradigm 
of using molecular assembly as a toolbox to achieve functional nanostructures, to a new 
area which is specifically focused on the direct assembly of functional molecules (e.g. 
drugs, or imaging agents) into nanostructures of their own. 
6.2  Introduction 
  Drugs are a special class of chemicals that produce a biological effect when 
administered to a living organism. In clinical practice, drugs are often co-
administered with other substances, such as excipients, stabilizers, solvents, or even 
other drugs, to maximize the therapeutic effects while minimizing the possible side 
effects. Given the low therapeutic index of most anticancer drugs (the ratio of the 
lethal or toxic dose to the therapeutic dose) and their great toxicity toward healthy 
cells, it is important and desirable to maintain a high therapeutic level of drugs only in 
the tumour sites.
261 
Over the past three decades, the use of nanoscale carriers to 
modify the drug’s pharmacokinetic properties and biodistribution profiles has been 
the primary focus of research in the drug delivery community, with the goal of 
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achieving targeted delivery to tumour sites.
5,28,262-267  
Two main strategies have been 
actively pursued: the first involves covalently modifying hydrophobic drugs with 
hydrophilic polymers to form polymer-drug conjugates.
5,266,267
 The purpose of this 
conjugation is to improve drug solubility, to increase drug targeting efficiency and to 
reduce drug toxicity. The great advantage of this strategy is that the pharmacokinetic 
properties of the drug are determined by the molecular weight and characteristics of 
the conjugated polymers. However, this strategy is limited by the polydispersity in 
polymer length and drug loading per polymer chain, and also by the limited choice of 




  The other strategy is the use of well-defined nanoscale architectures, with 
drugs being either encapsulated within, or conjugated onto, the carriers.
28,262-264
 These 
nanocarriers often present well-defined size, shape and tuneable surface chemistries, 
allowing robust pharmacokinetic protocols independent of the drug encapsulated to be 
established. A great diversity of nanostructures have been evaluated for their potential 













Among these nanocarriers, self-assembled nanostructures are 
of particular interest because they can be readily prepared to assume a variety of sizes 
and shapes with adjustable surface chemistry through solution-state assembly 
processes. A further attraction is that these supramolecular carriers can dissociate into 
individual molecules that could be removed through renal clearance once their desired 
function is accomplished. The limitations of using nanostructured material as drug 
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carriers lie in three aspects. First, their drug carrying capacity is very low, typically 
below 5% (w/w). Second, there is an inherent difficulty to control and characterize the 
amount of drugs loaded in each particle. There will also be a loading variation from 
particle to particle, and as such the loading capacity only represents the averaged 
amount of drug loaded in the whole system. Finally, the long term toxicity of these 
synthetic nano-objects remains unclear. 
  Our strategy presented here is to devise approaches that enable anticancer 
drugs to directly assemble into discrete well-defined nanostructures. We first chose  
two amphiphilic drug molecules, methotrexate (MTX) and folic acid (FA), as proof-
of-principle building blocks to illustrate this concept (Figure 6-1A). MTX is an 
antifolate drug used for the treatment of blood, lung, breast, and other kinds of 
cancer.
277 
The mechanism by which MTX exerts its toxicity is through competitive 
inhibition of dihydrofolate reductase, possessing a one thousand-fold greater binding 
affinity than folate, which leads to eventual inhibition of DNA and RNA synthesis.
277-
279 
Folic acid is a biologically active molecule (also known as vitamin M or B9) that 
has several important functions in cell sustainability and proliferation,
280 
and has been 
recently reported to be an effective targeting ligand for various cancers.
281 
It is known 
that the pterin (2-aminopteridin-4-ol) moiety could potentially induce a particular 
arrangement of H-bonding interactions among four FA molecules.
282 
 Several studies 
have shown that the resultant Hoogsteen-bonded tetramers of folic acid or its 
derivatives can stack into chiral columns which further pack into ordered 
mesophases.
62,282-288 
Only in a few cases have discrete nanostructures formed by self-





 and to improve the mechanical properties of chitosan 
hydrogels.
290  
   The majority of anticancer drugs are, however, hydrophobic and do not 
possess the key amphiphilic feature to produce self-assembled discrete nanostructures 
in aqueous solutions.
256,257 
It is therefore necessary to incorporate a small hydrophilic 
segment onto the drugs of interest. Figure 6-1B illustrates the concept of design for a 
self-assembling drug amphiphile (DA). In this particular case, we conjugated a β -
sheet forming peptide onto the hydrophobic drug CPT to impart the necessary 
amphiphilicity for assembly into discrete nanostructures. This conjugation strategy 
has been extensively used by a few other groups to create self-assembling peptide 
amphiphiles,
75,106-108,291-293 
peptide nucleic acid amphiphiles,
110 
and amphiphiles 
containing either therapeutic agents
96,294-296
 or π-conjugated aromatic units.
276,297 
The 
peptides sequences used here serve as a structural control unit that play an important 
role in defining the final morphologies, providing the impetus for one-dimensional 
elongation through β-sheet formation. CPT constitutes not only the bioactive 
component of the drug amphiphile,
298 
but is also the driving force for hydrophobic 
collapse that helps to initiate self-assembly.
256 
Its rigid nature and potential for π-π 
interactions provide further means of influencing the nanostructure morphology 
formed. Herein, we discuss how solution processing of the nanotube-forming, four 
CPT-containing drug amphiphile can affect the self-assembly mechanism and provide 
insight into the stability of such structures. 
  In both cases of using anticancer drugs as building units, the resulting self-
assembled drug nanostructures will 1) have a high drug loading capacity (up to 100% 
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if the nanostructure is made of free drug), 2) allow for a quantitative control of the 
drug content in each drug carrier since the assembled nanostructures have the 
identical drug content as the individual molecule, and 3) can minimize the toxicity of 
using additional synthetic carriers. 
  
Figure 6-1. Chemical structures of natural and synthetic drug amphiphiles used in this 
study.(A) Both methotrexate and folic acid contain a glutamic acid residue (marked in 
blue) and can be regarded as amphiphilic molecules when deprotonated at a higher pH. 
(B) The creation of camptothecin (CPT) drug amphiphiles by conjugating four CPT 
molecules to one β-sheet forming peptide via a biodegradable linker. Two β-sheet 
forming sequences (VQIVYK and NNQQNY) were used to create two drug amphiphiles: 
qCPT-buSS-Tau and qCPT-buSS-Sup35. The linker used to bridge the drug and the 
peptide is responsive to glutathione, a reducing agent within cells. 
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6.3  Experimental Procedures 
6.3.1 Materials 
  Folic acid and methotrexate were purchased from Sigma-Aldrich and used as 
received. Fmoc amino acids, Rink Amide resin and coupling agents (HBTU and 
HATU) were sourced from AAPPTEC (Louisville, KY) and camptothecin was 
obtained from Avachem (San Antonio, TX). Borate buffer, consisting of sodium 
borate decahydrate and sodium hydroxide, was purchased from RICCA Chemical 
Company. 10×DPBS (Dulbecco’s Phosphate Buffered Saline without calcium or 
magnesium) was purchased from Lonza. 
  Buffer solutions used in the FA and MTX studies were prepared using the 
following protocols: Borate buffer (pH 9.5) was used as received; 1×DPBS solution 
(pH 7.4) was prepared by 10-fold dilution of 10×DPBS with water; 0.1M sodium 
acetate buffer (pH 5) was prepared by mixing 71.4mL of 0.1M acetic acid and 
128.6mL of 0.1M sodium acetate solutions. The pH values of all buffered solutions 
were measured by a pH meter (Mettler Toledo) using an InLab Micro pH electrode. 
The solution containing 1 wt% FA was prepared by adding 5.1mg FA to 500µL of 
each buffer solution and vortexing until clear. The final pH of the solution was 
subsequently re-adjusted to the initial pH of the original buffer solution by the 
addition of 1M NaOH or 1M HCl. 
6.3.2 Peptide Synthesis 
  The peptide, qCys-Sup35, was synthesized using a combination of automated 
(Focus XC, AAPPTEC) and manual solid-phase Fmoc peptide synthesis techniques. 
Branching lysines were introduced through the use of Fmoc-Lys(Fmoc)-OH 
 
 89 
(Novabiochem, San Diego, CA). The peptide was cleaved from the resin using a 
mixture of trifluoroacetic acid, triisopropylsilane, water and ethanedithiol 
(90:5:2.5:2.5) for 2 h, isolating the crude peptide by trituration into cold diethylether. 
Purification to >95% homogeneity was performed using reversed-phase HPLC and 
identifying product fractions by MALDI-TOF mass spectrometry. The desired 
fractions were then lyophilized to give qCys-Sup35 as a white solid. 
 
6.3.3 Drug Amphiphile Synthesis 
The synthesis of the four CPT-containing drug amphiphile, qCPT-Sup35, was 
accomplished through the reaction of the peptide qCys-Sup35 with the activated 
disulphide, CPT-buSS-Pyr (prepared as described previously
256
). Briefly, qCys-Sup35 
(15 mg, 6.8 μmol) and CPT-buSS-Pyr (22.8 mg, 40.8 μmol) were dissolved in N2-purged 
DMSO (2 ml) and allowed to react for 2 days. The resulting pale yellow solution was 
then diluted to ~18 ml with 0.1% aq. TFA (adding MeCN as required to solubilise any 
unreacted CPT-buSS-Pyr). The solution was then purified by reversed-phase HPLC, 
collecting and lyophilizing the desired product fractions. The resulting powder was 
dissolved in H2O and MeCN and aliquotted into cryo-vials, before re-lyophilization. The 
CPT content was calibrated using a disulphide reduction method and HPLC analysis, 
indicating that the final yield was 6.8 mg (33%). 
6.3.4 Transmission Electron Microscopy 
  A drop containing 3-5 µL of liquid samples was loaded onto a carbon-copper 
TEM grid. Sample solutions were wicked away with a piece of filter paper to result in 
a thin liquid layer on the grid, and were left to dry for 10 minutes. Next, the dried 
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samples were stained with 5 µL of 2% uranyl acetate aqueous solution. After 
approximately 10 seconds, excess staining solution was wicked away, and the TEM 
samples were left to dry for at least 3 h before TEM imaging with a Philips EM 420 
TEM equipped with SIS Megaview III CCD digital camera. 
 
6.3.5 Circular Dichroism Measurement 
  All circular dichroism (CD) spectra were measured at room temperature using 
a Jasco J-710 circular dichroism spectrophotometer. In order to obtain consistent CD 
measurements, samples were diluted 10-fold from 1% to 0.1% FA immediately before 
each measurement to avoid high tension (HT) values above 800V. A final volume of 
200 µL samples were loaded into a 1 mm pathlength cuvette and measurements were 
obtained from 200 to 450 nm with 0.5 nm data pitch, 200 nm/min scan speed, 2 s 
response time, and 2 nm band width. The CD spectrum of each sample is the average 
of 3 measurements with background subtraction and was smoothed by an integrative 
package in IGOR software. 
6.4  Results and Discussions 
6.4.1 Self-assembly of Folic Acid in Methanol-Water Mixtures 
  We found that folic acid has a low solubility in pure Milli-Q water but will 
immediately form a yellowish self-supporting gel upon dissolution in methanol at a 
concentration of 1% or above (w/v). TEM imaging reveals dominant filamentous 
nanostructures (Fig. 6-2A) with a diameter of 4.2 ± 0.5 nm. Inspired by the work of 
using mixed solvents to control solution-state self-assembly of block copolymers,
299-
301 
we explored the effect of water-methanol mixtures on the FA assembly. Samples 
 
 91 
were prepared using two different mixing protocols: a step-wise method and a 
premixed solvent method.  
 
Figure 6-2. TEM images of self-assembled filamentous nanostructures and micron-sized 
platelets formed by 1 wt% folic acid in mixtures of methanol and water. The samples 
were prepared through a stepwise mixing method through which folic acid was first 
dissolved in methanol with subsequent addition of water to reach the desired mixing 
ratio. Filamentous nanostructures were observed as the dominant morphology in solution 
samples containing 100% (A), 80% (B), and 70% (C) methanol, with a diameter of 
4.2±0.5 nm, 3.5±0.5 nm and 3.9±0.6 nm respectively. Lozenge-shaped platelets of 
micron size were dominant in solutions containing 50% (D), 25% (E) and 0% (F) 
methanol. 
 In the step-wise method, FA was first dissolved in an appropriate amount of pure 
methanol, followed by the addition of water in a step-wise manner to reach the desired 
mixing ratio of methanol to water (v/v). The concentration of FA in all the studied 
solutions was fixed to be 1% (w/v). TEM imaging was performed after aging the 
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solutions overnight. As shown in Fig. 6-2, similar filamentous nanostructures were 
observed as the dominant morphology in both 80% (Fig. 6-2B) and 70% (Fig. 6-2C) 
methanol solutions, with respective diameters of 3.5 ± 0.5nm and 3.9 ± 0.6 nm. The 
sample containing 80% methanol also formed a self-supporting gel, similar to the gel 
formed in pure methanol. Both could restore the gel state within seconds after vigorous 
vortexing. The 70% methanol solution on the other hand, while containing a significant 
amount of nanofibers, presented as a free flowing liquid only. Occasionally, a few 
lozenge-shaped platelets could be seen by TEM imaging. 
  These lozenge-shaped platelets became the dominant structures in solutions 
containing 50% or more water (Figs. 6-2D-F). On the basis of our TEM observations, 
most platelets appeared to be single layered, although some multi-layered platelets 
can also be seen. Frequently, these platelets broke into two halves or even smaller 
fragments, and thus lost their sharp edges and lozenge shape identity (Fig. 6-2F). The 
Figure 6-3. Circular dichroism spectra of 1wt% folic acid solutions in methanol-water 
mixtures of varying compositions, prepared by two different methods: step-wise addition 
of water to a methanolic solution of folic acid (A) and dissolution of folic acid in pre-
mixed methanol-water mixtures (B). 
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regular shape and dimension of the observed platelets are strongly reminiscent of 
those of polymer single crystals,
302 
suggesting that the FA molecules are packed in a 
well-defined order within these platelets.  
  Circular dichroism (CD) spectroscopy reveals induced supramolecular 
chirality in both filamentous nanostructures and micron-sized platelets. The CD 
spectrum of FA in pure water (Fig. 6-3A, black curve) shows positive bands at 225, 
279, and 308 nm, a coupled band centred at 345 nm with two extremes at 328 nm and 
362 nm, and a negative peak at 375 nm. All the absorptions above 300 nm are 
ascribed to the pterin ring which has been shown to have UV–Vis absorptions both at 
280nm and around 350 nm in chloroform.
285,286 
We speculate that the positive band at 
279 nm could be the superposed π-π* transitions of the pterin ring and the aromatic 
group adjacent to the glutamic acid. The CD band at 225 nm most likely corresponds 
to the n–π* transition of the benzamide group (between the glutamic acid and benzene 
moieties).  
  In pure methanol where FA assembles into filamentous nanostructures, the CD 
spectrum is dramatically different (Fig. 6-3A, red curve), displaying two negative 
signals at 225 nm and 273 nm and a weaker, broad positive band around 290 nm. 
Although FA possesses only one chiral carbon on the glutamic acid, it is not clear to 
us whether the observed supramolecular chirality is induced solely by glutamic acid 
packing, or is also affected by the packing of tetramerized pterin rings. It is clear, 
however, that the differences in CD spectra collected in water and in methanol are a 
direct reflection of internal chiral packing order. The negative absorption at 225 nm in 
pure methanol is similar to the characteristic CD absorption of β-sheets, though 
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slightly red shifted. This shift may be due to a combination of the amide being 
connected to an aromatic moiety and the difference in solvent polarity between water 
and methanol. Nevertheless, the similarity indicates that glutamic acid may pack in a 
similar fashion to that found in β-sheet assemblies, helping to propagate the one-
dimensional elongation. It is highly possible that the adjacent aromatic group, under 
the direct influence of this chiral packing, is induced to give rise to a similar negative 
absorption around 270 nm. With increasing water content in the step-wise method, 
both negative absorptions became positive in amplitude and gradually intensified, and 
at the same time the positive absorptions linked to the pterin rings became stronger. 
The observed change in sign of absorption suggests a different packing order between 
the filaments and the platelets. Also, the increasing intensity of the CD band around 
280 nm as the methanol percentage decreases implies that more stable chiral 




Figure 6-4. TEM images of micron-sized, lozenge-shaped platelets at mixed solvents 
containing 80% (A), 70% (B), 50% (C) and 25% (D) methanol. The samples were 
prepared by directly dissolving folic acid into the mixed solvents with predetermined 
ratio to reach a final concentration of 1%. 
  We found the self-assembly of FA, particularly the formation of FA 
nanofibers, in methanol-water mixtures to be pathway-dependant. In the pre-mixed 
method, FA was directly dissolved in previously prepared water-methanol mixtures 
(80%, 70%, 50% and 25% v/v methanol). All solutions that were studied exhibited 
micro-lozenge formation only, with no evidence of any filamentous nanostructures 
(Figs. 6-4,A–D). CD analysis of these solutions indicated these structures possessed 
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the same secondary structure and packing modes as those formed by the step-wise 
addition method (Fig. 6-3B). These experiments suggest that water plays a significant 
role in the formation of the platelet structures, while methanol seems to favour the 
filamentous nanostructures. 
 The TEM studies and CD measurements collectively suggest that the observed 
nanofibers in pure methanol are one-dimensional stacks of FA tetramers. It has been 
shown by a number of laboratories that FA and its derivatives are capable of forming 
Hoogsteen-bonded tetrads through self-recognition of the pterin rings that contain both 
H-bond donors and acceptors.
283,286-288 
The resulting disklike tetramers can form one-
dimensional nanostructures that further stack into hexagonal mesophases.
283,286-288 
In the 
case reported here, the diameters of the nanofibers are in the range of 3.5 to 4 nm, which 
are in good agreement with the expected width of the disklike tetramers. Other evidence 
comes from the studies on the self-assembly of MTX. Our results showed that MTX 
could not form any well-defined nanostructures in all the studied conditions. In the case 
of MTX, the H-bond donor C=O in the pterin ring is replaced with the –NH2 group. This 
replacement appears to prevent it from forming the tetrameric disks that can aggregate 
into defined nanostructures. This is consistent with studies on the interaction of FA and 
MTX with the dihydrofolate reductase enzyme, which showed the two molecules binding 
with strikingly different orientations as a result of their differing H-bond donor/acceptor 
arrangements.
278,303 
It can therefore be concluded that, the formation of the tetrameric 
structure represents the first step toward the formation of all the observed morphologies. 
  The driving forces for one-dimensional stacking of tetrads could possibly stem 
from combined contributions of both the associative interactions between the 
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tetramerized pterin rings (π–π stacking) and the hydrogen bonding between the 
glutamic acid segments. In pure methanol, where only discrete nanofibers were 
observed, this stacking seems to be rather loose as the CD spectrum (Fig. 6-3A) 
reveals only the absorption bands linked to the glutamic acid and the adjacent 
aromatic ring, with the pterin moiety showing only weakly induced supramolecular 
chirality.  
 Addition of water into methanol solutions containing FA nanofibers leads to the 
transition from nanofibers to lozenge platelets. The stacking of the FA columns into 
lozenge platelets is likely driven by inter-fiber interactions of the C-terminal and side-
chain carboxylic acid groups. At the same time, the significant increase in the intensity of 
the pterin-associated CD signals also suggests changes in internal packing between the 
FA tetrads. It is therefore reasonable to assume that the supramolecular chirality of the 
pterin rings is linked to the crystalline packing among the FA columns. It is also possible 
that the increasing water content may affect the packing between the tetramerized pterin 




Figure 6-5. Proposed self-assembly pathways of folic acid into nanofibers and micro-
lozenges. The pterin ring of folic acid (I) interacts with two adjacent folic acid molecules 
through Hoogsteen H-bond to form disklike tetramers (II). These tetramers stack up in a 
rotated manner (III) to form a nanofiber (IV) in methanol. These stacked columns can 
further associate to give lozenge-shaped platelets in water (V). Addition of water into 
nanofiber-containing methanol solution leads to a morphological transition into platelets. 
6.4.2 Self-assembly of Folic Acid at Different pH 
  The proposed model in Figure 6-5 leads us to assume that at relatively higher 
pH values, at which carboxylic acid groups became highly deprotonated, the 
electrostatic repulsions will likely dissociate the lozenge platelets into individual 
nanostructures. We therefore carried out a series of experiments using three different 
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buffers: sodium acetate buffer (buffer zone: ~5), phosphate buffered saline (buffer 
zone: ~7.5), and borate buffer (buffer zone: ~9.5). FA was directly dissolved in the 
buffered solutions and their pH was carefully monitored and readjusted to be within 
their respective buffer zones if necessary. FA was found to have a very low solubility 
in acetate buffer. Fig. 6-6A reveals that fragmented platelets were the dominant 
nanostructure formed under these conditions. It should be noted that a 1 wt% solution 
of FA in pure water is also around pH 5, and so it would be expected that a buffered 
solution at this pH would give similar structures. At pH 7.4 (1× DPBS buffer) FA was 
observed to self-assemble into 1D nanostructures with an average diameter of 4.1 ± 
0.4 nm (Fig. 6-6B). These nanofibers are remarkably similar to those formed in pure 
methanol. At pH 9.5 (borate buffer), much shorter nanofibers were observed with an 
average diameter of 4.0 ± 0.4 nm. It is very likely that electrostatic repulsions among 
glutamic acid segments as a result of almost complete deprotonation at this pH are 




Figure 6-6. TEM images of folic acid formed at three different buffers (A-C) and their 
corresponding CD spectra (D). (A) Sodium acetate buffer (pH 5), (B) 1DPBS (~pH 7.4), 
and (C) borate buffer (~pH 9.5). 
 CD measurements were then obtained to probe the internal structure of the FA 
assemblies formed at three buffered solutions (Fig. 6-6D). Nanofiber-dominated samples 
in both buffered solutions (1×DPBS and borate) consistently showed a characteristic 
negative peak around 220–225 nm, indicative of the n→π* transition of the amide group. 
However, compared to the CD spectra collected from pure methanol, the CD signals of 
FA in 1×DPBS and borate buffers did not exhibit the negative peak at 273 nm that was 
observed for the pure methanol samples, instead showing a very weak positive band. The 
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reason for this may lie in the nature of the solvent system used. Since methanol is less 
polar than water, the spacing between the stacked tetrads may be increased as there is less 
need to shield the more hydrophobic pterin rings from the bulk solvent.
304 
This would 
lessen interactions between adjacent layers, and as such the induced chirality would be 
determined to a great extent by the chiral packing between the glutamic acid segments, 
only giving rise to the negative signal observed at 273 nm. The aqueous buffers 1×DPBS 
and borate, on the other hand, are polar that may cause the layers to stack more tightly, 
thereby contributing greatly to the induced supramolecular chirality and shifting the 
signal toward a positive amplitude. 
 Similar to the CD spectra observed in water and aqueous methanol mixtures, 1 
wt% solutions of FA in water and sodium acetate exhibited almost identical intense 
pterin ring absorptions over the 270–400 nm range. In addition, the 225 nm CD signal 
due to the amide group had a positive amplitude for the water and sodium acetate 
buffer solutions, as previously observed for the platelet structures. These observations 
show a clear correlation with the morphology that is adopted and can be used as a 
predictor for the structure formed. Filamentous structures correspond to a negative 
peak in the 220–225 nm region, whereas the platelet structure is indicated by a 
positive peak in the 220–225 nm region and multiple strong pterin ring absorptions. 
Comparing the results from the buffered solutions, it is clear that the stacking of 
the filamentous structures to form the micro-lozenges is dependent upon shielding of the 
carboxylic acid groups of the glutamate residue. In pure water, methanolic water and 
sodium acetate buffer, there is partial shielding of the negative charges that allows the 
filaments to pack together and ultimately yield the platelet structure. It is likely that water 
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will help to bridge the filaments through hydrogen bonding interactions. In 1×DPBS and 
borate, however, there is insufficient shielding and the negative charges introduce strong 
repulsive forces between the individual filaments that prevents association with one 
another. Accordingly, only one-dimensional structures are observed in these conditions. 
The case of methanol is likely different as this less polar solvent will favour the more 
protonated state of the carboxylic acids due to its lower ability to solvate charges. The 
lack of micro-lozenge structure is therefore a consequence of methanol being unable to 
act as a hydrogen bonding bridge between the carboxylic acids. 
6.4.3 Nanotubes Formed by Self-assembly of CPT Amphiphiles 
 The conjugation of a peptide segment with overall hydrophilicity onto the 
hydrophobic drug camptothecin creates amphiphilic molecules that could potentially 
self-assemble into discrete nanostructures in an aqueous environment.
256,257 
The 
resulting supramolecular nanostructures, regardless of the size, shape, or 
morphologies, would contain the same drug loading as the individual molecule. Here 
we discuss our efforts to probe the self-assembly pathway of drug amphiphiles (DAs) 
that were found to form a nanotube morphology. These DAs were synthesized by 
attaching four CPT molecules to a β-sheet-forming peptide. In this study, we used 
peptide sequences derived from the Tau protein
305
 and the Sup35 yeast prion
146
 that 
are both capable of forming parallel β-sheet assemblies. After conjugation with four 
CPT units, the drug loadings are 38% (w/w) for qCPT-Tau and 36% (w/w) for qCPT-
sup35. 
 The self-assembly of the two synthesized drug amphiphiles was initially 
probed by dissolving the respective conjugates into water (100 μM) and using TEM to 
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determine the assembly morphology. It can be seen from Fig. 6-7 that both qCPT-Tau 
(Fig. 6-7A) and qCPT-Sup35 (Fig. 6-7B) formed nanotubes with outer diameters of 
9.5 ± 1.0 nm and 9.9 ± 1.1 nm, respectively. The tubular morphology is inferred by 
the dark centre line throughout the observed filamentous morphologies due to the 
preferential deposition of the staining agent uranyl acetate onto the collapsed cores. 
These results also suggest that the replacement of the Tau β-sheet-forming peptide 
with the Sup35 β-sheet-forming peptide has little or no effect on the nanostructure 
morphology. The only notable difference was the longer contour length of the Sup35-
based nanotubes, which may be due to the greater solubility of this conjugate 
compared with the Tau-based conjugate. CD spectroscopy further reveals that the two 
assembled conjugates possess similar packing arrangements (Fig. 6-7C), with both 
displaying excitonic coupling that arises from electronic interactions between 
neighbouring CPT units. Strong β-sheet signals can also be seen for both conjugates, 
albeit red-shifted to around 224 nm from the typical value of 216 nm. We noted that 
the organic solvent DMSO can disrupt the nanotube structures, as the CD spectrum of 
Figure 6-7. Representative TEM micrographs of nanotubes formed by qCPT-Tau (A) 
and qCPT-Sup35 (B) in water at 100 M. TEM samples were negatively stained with 
2% uranyl acetate. (C) Circular dichroism spectra of qCPT-Tau in water (1 M) and 
DMSO (500 nM), and qCPT-Sup35 (50 M) in water. 
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qCPT-Tau in DMSO only displays a weak negative signal, most likely due to the 
drug’s own chirality. 
We found that assembly into nanotubes is also a path-dependent process. In 
these experiments, we first used hexafluoroisopropanol (HFIP) to break any pre-
existing aggregates formed by the conjugates during purification and lyophilisation. 
HFIP is a fluorous solvent commonly used for the solubilisation of amyloid-forming 
peptides. We chose HFIP over DMSO as its volatility allows for easy removal. After 
removal of HFIP, the qCPT-Sup35 residue was reconstituted in water to reach a final 
concentration of 100 μM, however a turbid solution was formed that contained visible 
aggregates. TEM imaging after overnight aging did not show any dominant well -
defined structures except for the occasional observation of several short fibers or 
tubes (Fig. 6-8B). We speculate that the thin films formed upon drying of the HFIP 
solution were too insoluble in water, possibly due to strong interactions among the 
CPT segments that prevented any structural rearrangement on our experimental 
timescale. However, when a mixture of water and acetonitrile (50/50) was used to 
reconstitute the HFIP-treated sample, a clear solution was formed immediately. 
Interestingly, TEM imaging (Fig. 6-8C) shows nanofibers to be the dominant 
structure rather than the tubular morphology formed without HFIP-treatment (Fig. 6-
8A). The diameter of these nanofibers is 5.8 ± 0.7 nm, a value much smaller than the 
outer diameter of the nanotubes (9.9 ± 1.1 nm), indicative of a possible core-shell 
micellar structure. CD spectroscopy of this solution (Fig. 6-8D) shows that the level 
of electronic interaction between CPT units is strongly diminished in comparison to 
that of the nanotube morphology, with no bisignate peaks observed in the CPT 
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absorption regions. The continued presence of the peak around 389 nm does, 
however, suggest that there still exist some CPT–CPT interactions, perhaps due to 
interactions between CPT molecules of the same conjugate. It is also evident that the 
CD spectrum of the nanofiber solution exhibits a more typical β-sheet signal at 216 
nm, rather than the red-shifted and more intense signal observed for the nanotube 
structure. These experiments reveal that even for small molecule amphiphiles, the 
resulting self-assembled structure could still be kinetically trapped due to the 
involvement of molecular interactions such as hydrogen bonds or π-π interactions that 












6.5  Conclusion  
  In this discussion, we reported our work on the self-assembly of small 
molecule drugs in dilute solutions. First of all, we demonstrated the possibility of 
Figure 6-8. TEM micrographs of the assembled structures formed by qCPT-Sup35 via 
different preparative pathways. Nanotubes of qCPT-Sup35 were observed after 
dissolution in water at 100 M after peptide purification (A). Only very few short 
nanofibers were observed upon reconstitution of qCPT-Sup35 in water at 100 M after 
initial lyophilization from HFIP (B). Core-shell nanofibers were observed as the 
dominant structures when qCPT-Sup35 was reconstituted at 50 M in 50% aqueous 
MeCN after initial lyophilization from HFIP (C). All TEM samples were negatively 
stained by 2% uranyl acetate. (D) CD spectra of qCPT-Sup35 in H2O (solid line, 50 M), 
where nanotubes are the dominant self-assembly morphology, and qCPT-Sup35 in 50% 
aqueous MeCN after lyophilization from HFIP (dashed line, 50 M). The latter process 
of solution preparation favors the formation of single filaments rather than nanotubes. 
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using drug molecules as molecular building blocks to create discrete supramolecular 
nanostructures. We showed that the free folic acid can assemble into both nanofibers  
and micro-sized lozenges depending on the solvent conditions and mixing procedures. 
In the case of hydrophobic anticancer drugs, conjugation to a peptide segment with 
overall hydrophilicity presents an effective strategy to create self-assembling drug 
amphiphiles that have the ability to assemble into discrete nanostructures. Second, we 
demonstrated the tunability of the resulting supramolecular nanostructures, for 
example, the morphological transition from nanofibers to lozenges for folic acid, and 
also the transition from nanotubes to nanofibers in the case of CPT drug amphiphiles. 
Third, we demonstrated the complexity of assembling small molecule drugs. Unlike 
traditional low-molecular-weight surfactants which are known to assemble into 
dynamic, thermodynamically stable micellar structures, small molecule drugs often 
posses the ability to form strong intermolecular interactions such as hydrogen 
bonding, or π-π interactions. These strong interactions are critical for the drug’s 
biological functions. The presence of these interactions is twofold: on one hand, it 
allows for the formation of stable, far-from-equilibrium nanostructures in dilute 
solutions. Stability is often a very important consideration in the design of 
supramolecular drug carriers. On the other hand, it results in difficulties in 
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7 Conclusions and Future Work 
7.1  Conclusions 
 The main objective and motivation for this dissertation is to explore the 
incorporation of peptide-based material with various anticancer drugs and imaging 
agents, ultimately transforming them into supramolecular nanostructures. Based on their 
applications, nanostructures of different shapes (spherical and cylindrical) and surface 
charges (cationic and anionic) have been generated. In addition, enzymatic-responsive 
feature has been integrated in a few examples to confer a triggered-release mechanism 
within the nanostructure. Coupled with a rational design of peptide design, the 
hydrophobic nature of anticancer drug and imaging agents demonstrated a self-sufficient 
building unit for nanostructure self-assembly. 
 Chapter 2 and 3 present the beacon probe concept with a degradable peptide 
linker, primarily focused at the diagnostic aspect for enzyme detection, which is often 
overexpressed in cancer cells. As a proof of concept, the supramolecular nanobeacon is 
resistant to nonspecific enzymatic degradation in the self-assembled state but can be 
effectively activated by target enzyme in the monomeric form. The manipulation of 
peptide design enables morphological transition and customizable charge property on the 
surface of nanostructures. Our studies showed that cationic spherical nanostructure has 
higher cellular uptake than its anionic and cylindrical counterparts. In Chapter 4, a 
fluorescing anticancer drug is utilized to construct the drug beacon with a degradable 
linker. This design possesses both therapeutic and diagnostic attributes, and it is 
activatable by a specific enzyme.  
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 In Chapter 5, an anticancer drug with inherent MRI signal was implemented with 
a self-assembling peptide sequence, generating one-dimensional nanofibers hydrogel.  
This work has demonstrated the feasibility of monitoring CEST MRI agent in vivo, and 
more importantly, anticancer drug with this intrinsic property can be engineered to 
bestow a new mechanistic aspect, such as biodegrable hydrogel. Chapter 6 mainly studied 
and discussed the self-assembly of natural and synthetic amphiphilic drug into discrete 
nanostructures. The findings revealed the importance of native chemical structure and 
their intermolecular interaction in directing the self-assembly of nanostructures. Besides, 
the solvent mixture and processing conditions could fundamentally affect the final state 
of self-assembled structures.  
7.2  Future Work 
While great advances has been made in this dissertation to devise peptide-based 
materials for cancer diagnostic and drug delivery systems, further efforts are needed to 
improve current constructs and have a better understanding in the design principle. The 
following sections discussed several interesting directions that can be pursued to achieve 
these goals. 
7.2.1 Targeted Delivery 
 There are several targeted delivery approaches that can be incorporated to 







 and non-peptidic ligands
310,311
. While two antibody-drug 
conjugates
312,313
 have shown great success in the market, other targeting ligands could 
potentially undergo clinical translation in the near future. Considering the peptide-based 
self-assembly platform, peptide targeting ligands present the highest compatibility and 
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, SP5-52 (sequence: SVSVGMKPSPRP)
318
, 
PIVO-8 (sequence: SNPFSKPYGLTV) and PIVO-24 (sequence: YPHYSLPGSSTL)
319 
have been explored intensively and showed promising results with increasing therapeutic 
efficacy. Interestingly, a nine-amino cyclic peptide, LyP-1 (sequence: CGNKRTRGC)
320 
demonstrated both tumor-targeting capability and cytotoxic activity on its own. Such 
peptide with multiple functionalities, are of great interest and can be rationally 
improvised to transform it into a self-assembling nanostructure. In addition, folate-
targeting and prostate-specific membrane antigen (PSMA) ligands are two ideal 
candidates for future modifications. The conjugation of targeting ligands to nanobeacon 
or drug beacon systems could potentially increase the specificity of tumor site 
accumulation; however, the choice of ligands should be thoroughly considered to retain 
the overall amphiphilicity requirement for self-assembly process. 
7.2.2 Self-assembling CEST MRI Nano-Systems 
 Numerous research groups have progressively discovering and exploring new 
small molecule CEST MRI contrast agents for in vivo imaging applications. McMahon 
and co-workers reported a series of salicylic acid and analogues
249
 as well as anthranilic 
acid analogs
321
 possess diamagnetic CEST MRI property with desirable signals far from 
water peak. The incorporation of these small molecule CEST contrast agents to self-
assembling peptide is worth exploring to generate novel nanostructure imaging systems 
or theranostic systems with the addition of therapeutic agents. From a fundamental stand-
point, the CEST MRI property under highly-dense molecular arrangement of self-
assembled state could be further explored and investigated. Furthermore, CEST contrast 
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agents encapsulated within liposome structure have shown enhancement in CEST 
signal.
322,323 
The combination of CEST constrast agent with self-assembling peptide 
directed to nanovesicle formation
324,325
 would create similar intra-liposomal aqueous 
environment that could potentially enhance CEST signal. These explorations can greatly 
expand the field of CEST MRI imaging as well as crafting innovative functionality to 




Supporting Information for Chapter 2 
Design and Construction of Supramolecular Nano-Beacons for 
Enzyme Detection 
 
S1 Synthesis and Characterization of Peptide Molecules 
S1.1 Materials 
All Fmoc amino acids were purchased from Advanced Automated Peptide Protein 
Technologies (AAPPTEC, Louisville, KY) and Rink Amide MBHA resin was purchased 
from Novabiochem (San Diego, CA). 5-Carboxyfluorescein (5-FAM) was purchased 
from AnaSpec, Inc. (Fremont, CA) and Black Hole Quencher1 carboxylic acid (BHQ-1-
CO2H) was purchased from Biosearch Technologies, Inc. (Novata, CA). Cathepsin-B 
(bovine spleen) was purchased from EMD Chemicals (San Diego, CA). 
S1.2  Synthesis 
Standard 9-fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis was 
used to synthesize the TAT sequence and the enzyme degradable linker (Fmoc-
GFLGK(Mtt)GRKKRRQRRRPPQ-Rink) on a 0.25 mmole scale. This procedure was 
carried out using the Focus XC automated peptide synthesizer (AAPPTEC, Louisville, 
KY). For TFB and TF molecules, 5-carboxyfluorescein (5-FAM) was manually coupled 
at the peptide N-terminus (after Fmoc removal) with 5-FAM/HBTU/DIEA at a ratio of 
4:4:6 relative to the peptide, shaking overnight at room temperature. For TFB and TB 
molecules, Black Hole Quencher-1 (BHQ-1) was coupled to the Lys ε-amine (after Mtt 
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removal) with BHQ-1/HBTU/DIEA at a ratio of 1:0.96:1.7 relative to the peptide, 
shaking overnight at room temperature. Fmoc deprotections were performed using a 20% 
4-methylpiperidine in DMF solution for 10 minutes, repeating once. Mtt deprotections 
were carried out using a mixture of TFA/TIS/DCM with a ratio of 3:5:92 for 5 minutes, 
and the procedure was repeated twice. Acetylation was performed on TF and TB 
molecules at the Lys(Mtt) side chain amine and the N-terminal amine, respectively, using 
a 20% acetic anhydride in DMF solution with 100 µL of DIEA, shaking for 15 mins, and 
repeating once. In all cases, reactions were monitored by the ninhydrin test (Anaspec 
Inc., Fremont, CA) for free amines. Completed peptides were cleaved from the solid 
support using a mixture of TFA/TIS/H2O in a ratio of 95:2.5:2.5 for 3 hours. Excess TFA 
was removed by rotary evaporation and cold diethyl ether was added to precipitate the 
crude peptide, which was collected and dried under vacuum overnight. 













Scheme S1: Synthesis steps of TFB 
 
1.20% 4-methylpiperidine in DMF 
2. 5-FAM, HBTU, DIEA, DMF 
1.  
1. 3% TFA, 5% TIS in DCM 










1.20% 4-methylpiperidine in DMF 
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1. 3% TFA, 5% TIS in DCM 
2. BHQ-1, HBTU, DIEA, DMF 
1.20% 4-methylpiperidine in DMF 




The peptides were purified by preparative RP-HPLC using a Varian Polymeric 
Column (PLRP-S, 100 Å, 10 µm, 150 × 25 mm) at 25
o
C on a Varian ProStar Model 325 
preparative HPLC (Agilent Technologies, Santa Clara, CA) equipped with a fraction 
collector. A water/acetonitrile gradient containing 0.1 % v/v TFA was used as eluent at a 
flow rate of 25 mL/min, monitoring the absorbance at 480nm and 534nm for TF and 
TB/TFB molecules respectively. The crude materials were dissolved in 30 ml of 0.1% 
aqueous TFA, and each purification run was carried out with a 10 ml injection. Collected 
fractions were analyzed by ESI-MS (LDQ Deca ion-trap mass spectrometer, Thermo 
Finnigan, San Jose, CA) and those containing the desired product were further 
concentrated by rotary evaporation to remove acetonitrile. The remaining solution was 




S1.4 MALDI-ToF Characterization 
High resolution peptide masses were determined by MALDI-ToF mass 
spectrometry, using a BrukerAutoflex III MALDI-ToF instrument (Billerica, MA). 
Samples were prepared by depositing 1 µL of sinapinic acid matrix (10 mg/ml in 0.05% 
TFA in H2O/MeCN (1:1), Sigma-Aldrich, PA) onto the target spot, and allowed to dry 
for 5 minutes. 1 µL of peptide aqueous solution (0.1% TFA) were deposited on the 
corresponding spot and quickly mixed with 1 µL of sinapinic acid matrix solution. 







Table S1: Expected and observed masses of the synthesized molecules 
MALDI-ToF Exact Mass Observed Mass [M+H
+
] 
TFB 3063.607 3064.139 
TF 2619.416 2621.686 

























































Figure S1. MALDI-ToF spectra of (a) TFB, (b) TF and (c) TB molecules. 
S1.5 Analytical HPLC Characterization 
Analytical reverse-phase HPLC was performed using a Varian polymeric column (PLRP-
S, 100 Å, 10 µm, 150 × 4.6 mm) with 20 µL injection volumes. A water/acetonitrile 
gradient containing 0.1% v/v TFA at a flow rate of 1 mL/min was used and samples were 





























Figure S2. Reverse-Phase HPLC chromatograms of (a) TFB, (b) TF and (c) TB 
molecules. 
 
S2 TEM and Cryogenic TEM Sample Preparation 
S2.1 Transmission Electron Microscopy (TEM) 
5µL of sample solution was deposited onto a carbon-coated copper grid (Electron 
Microscopy Services, Hatfield, PA), and excess solution was wicked away using a small 
piece of filter paper. The sample was then left to dry for 10-15 minutes. Next, 5 µL of 2 







carefully removed using a piece of filter paper to leave a very thin layer of uranyl acetate 
aqueous solution on top of the pre-dried samples. This solution was allowed to dry at 
room temperature. Bright-field TEM imaging was performed on a FEI Tecnai 12 TWIN 
Transmission Electron Microscope operated at an acceleration voltage of 100 kV. All 
TEM images were recorded by a SIS Megaview III wide-angle CCD camera. 
S2.2 Cryogenic Transmission Electron Microscopy (Cryo-TEM) 
Cryogenic TEM imaging was also performed on the FEI Tecnai 12 TWIN 
Transmission Electron Microscope, operating at 80 kV. 3-5 µL of sample solution was 
placed on a holey carbon film supported on a TEM copper grid (Electron Microscopy 
Services, Hatfield, PA). All the TEM grids used for cryo-TEM imaging were treated with 
plasma air to render the lacey carbon film hydrophilic. A thin film of the sample solution 
was produced using the Vitrobot with a controlled humidity chamber (FEI). After loading 
of the sample solution, the lacey carbon grid was blotted using preset parameters and 
plunged instantly into a liquid ethane reservoir precooled by liquid nitrogen. The vitrified 
samples were then transferred to a cryo-holder and cryo-transfer stage which was cooled 
by liquid nitrogen. To prevent sublimation of vitreous water, the cryo-holder temperature 
was maintained below -170°C during the imaging process. All images were recorded by a 








S3  TEM image of TFB nanobeacons in DMEM  
 
 
Figure S3. TEM image of TFB NB in DMEM cell medium reveals dominant spherical nanoparticles of 
approximately 10 nm. The NB concentration was 250 µM in DMEM. The TEM sample was negatively 




S4 Supramolecular filaments of TB in borate buffer 
 
Figure S4. Supramolecular filaments formed by self-assembly of TB in borate buffer (pH 9.5) at a 
concentration of 200 µM. The diameter of these filaments is 12.5±0.9 nm, a value close to twice that of the 
fully extended length of the studied molecule, suggesting a cylindrical shape of the cross-sectional area.   
 
S5 Circular Dichroism Measurement 
CD spectra were recorded on a JASCO J-710 spectropolarimeter (JASCO, Easton, 
MD) and all three molecules of TFB, TF and TB were found to have a random coil 
secondary structure in 100 µM, 1xPBS solutions. All CD spectra were normalized using 
the equations below, where  mr is the mean molar ellipticity per residue
326
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M : molecular weight (g/dmol) 
c : concentration (g/cm
3
) 
l : path length (cm) 


























Figure S5. Circular dichroism spectra of (a) TFB, (b) TF and (c) TB molecules at 100 µM. These 
measurements were performed at room temperature. Spectra showed a negative peak at 199 nm and a 




S6 Enzymatic Degradation Experiment in Buffered Solutions 
S6.1 Cathepsin-B (CatB) Enzyme 
The reaction buffer containing 1 mM EDTA (enzyme stabilizer) and 25 mM L-
cysteine (enzyme activator) in 1×PBS solution was prepared. The solution pH was 
adjusted to 5.0 through the addition of 3 M HCl. The desired amount of cathepsin-B was 
added to the buffer solution and pre-incubated at 37°C for 5 minutes to activate the 
enzyme. Stock solution was prepared by dissolving 0.6 mg of TFB molecule with 500 µL 
of pH 5.0 reaction buffer, yielding a TFB concentration of 0.4 mM. 0.25 µL of 0.4 mM 
stock solution was added to each reaction well and mixed thoroughly with the pre-
incubated cathepsin-B solution. Cathepsin-B (Bovine Spleen) was purchased from EMD 
Chemicals (Gibbstown, NJ) and it was delivered in liquid form with stock concentration 
of 17 µM. Reaction kinetics was monitored using a Gemini XPS microplate reader 
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(Molecular Devices, Sunnyvale, CA). Samples were excited at 492 nm and 5-FAM 
emission was measured at 520 nm with a 515 nm cutoff.  
S6.2 Matrix Metalloproteinase 2 (MMP-2) Enzyme 
The reaction buffer containing 50mM Tris-HCl, 50mM NaCl, 10mM CaCl and 
0.05% Brij-35 was freshly prepared and the solution pH was verified to be around 7.4. 
TFB molecule of 1µM in 100µL of reaction buffer solution was pre-incubated at 37°C for 
5 minutes. Appropriate amount of MMP-2 (10nM – 40nM) from a stock solution of 
200nM was added to the pre-heated solutions. Active human recombinant MMP-2 
enzyme was purchased from EMD Millipore, Billerica, MA and was used as it is in all 
the relevant experiments. Reaction kinetics was monitored as described in S6.1. 
S7 Degradation Kinetics Comparison of CatB and MMP-2 Enzymes 
 
Figure S6. Reaction kinetics of 1000nM TFB molecules incubated with CatB and MMP-2 enzymes at 
different concentrations. 
Enzymatic degradation was carried in buffered solutions and 1000nM TFB 
molecules were incubated with different concentrations of CatB and MMP-2 enzyme. 
MMP-2 enzyme used in these experiments was relatively lower as the plasma 
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concentration of MMP-2 ranged from 10nM to 20nM (749µg/L - 1114µg/L).
327
 The 
fluorescence intensity of TFB that was incubated with MMP-2 enzyme remained flat at 
baseline while CatB enzyme showed an increasing trend suggested a selective 
degradation by CatB.  
 
S8 TFB Critical Micelle Concentration Determination 
 
Figure S7. Plot of TFB surface tension versus log of concentrations. The intersection of two different 
slopes of lines indicates TFB critical micelle concentration around 30µM. 
 
A 500µM of TFB stock solution were prepared in sodium acetate buffer (pH 5) 
and serial dilution method was used to prepare various concentrations of TFB samples to 
a final volume of 100µL. All samples were protected from light and left overnight at 
room temperature. Surface tension measurements were carried out using the pendant drop 
method
328
. Measurement apparatus includes micrometer syringe GE 2.0mL from Gilmont 
Instrument, dispensing needle 22 gauge x 0.5” blunt tip, and series of pendant drop 
images were taken by First Ten Ångstroms (FTA) 125. Surface tension measurements 
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were further analyzed using FTA32 software. From the plot above, TFB critical micelle 
concentration was determined to be 30µM at pH 5. 
 
S9 kcat/Km Calculation 
The catalytic reaction of CatB has been reported to follow the kinetic behavior 
described by the Michaelis-Menten equation. According to Michaelis-Menten Equation, 
the reaction rate V can be expressed in the following form: 
  
           
      
 
in which kcat is the first-order rate constant, [E]t is the total enzyme concentration, [S] is 
the substrate (TFB, in the case reported here) concentration, and KM is the Michaelis-
Menten constant. At the very low substrate concentrations reported herein ([S]<<KM), the 
equation can be rewritten as: 
  
    
  
        
The ratio of kcat/KM provides a direct measure of enzyme efficiency and 
specificity. The plot in Fig. 4D is in good agreement with this equation as the initial 










S9.1 Enzymatic Cleavage Experiments at a Concentration of 1 µM NB Molecule 
 
Figure S8. (a) Reaction kinetics for 1000 nM TFB with different concentration of Cathepsin-B 
enzyme. (b) Plot of initial cleavage rate over Cathepsin-B concentration after unit conversion 





This series of experiments were carried out with constant substrate concentration, 
1000 nM TFB and various Cathepsin-B concentrations. The maximum fluorescence 
intensity at 200 minutes was assumed to correspond to 100% cleavage of 1000nM TFB, 
releasing 1000 nM 5-FAM molecule and therefore yielding       RFU. 
                
         
           
 
 
For example: Initial Cleavage Rate for 1000nM TFB with 2000nM CatB is 176.28 
RFU/min. 
 
                  
   
   
 
           
         
 
    
      
       
       
   
 
 
By using the same method, each initial cleavage rate (V) was calculated and plotted in 
Figure 8(b). 
 
      
 
    
           
       
           
 
 
From Michaelis-Menton equation, 
 
  
    
  






    
 
    
  
    
 




    
 
   
 
 
            
 
    
           
       
           
 
 
    
  
           
       
           
   
 
           
 
 
    
  
 
          
      
 
          
 
 
    
  
       




     
 
S9.2 Enzymatic Cleavage Experiments at a Concentration of 50 µM NB Molecule 
 
Figure S9. (a) Reaction kinetics for 50 µM TFB with different concentrations of Cathepsin-B enzyme. 






This series of experiments were carried out with 50,000 nM TFB and various 
concentrations of Cathepsin-B enzyme. Due to the high concentration of TFB, enzymatic 
reaction would take much longer time to reach completion. Therefore, the unit conversion 
in this experiment was assumed to be the same as the previous experiment, and the 




                
         
             
 
 
For example: Initial Cleavage Rate for 50,000nM TFB with 2500nM CatB is 9.06 
RFU/min. 
 
               
   
   
 
             
         
 
    
      
       
       
   
 
 
By using the same method, each initial cleavage rate (V) was calculated and plotted in 
Figure 9(b). 
      
 
    
           
       
           
 
 
            
 
    
           
       
           
 
 
    
  
           
       
           
   
 
             
 
 
    
  
 
           
      
 
          
 
 
    
  
        














S10 Effect of Varying TFB Concentrations 
 
Figure S10. Reaction kinetics of Cathepsin-B (1000nM) incubated with various concentrations of 
TFB (50nM to 5000nM). 
Cathepsin-B enzymatic degradation kinetics was performed with different TFB 
concentrations, 50nM to 5000nM and enzyme concentration was fixed to 1000nM. At 
lower concentration The cleavage rate increases as TFB concentrations increases from 
50nM to 1000nM, however, a decreasing trend of reaction rate was observed for higher 
TFB concentration, 3000nM and 5000nM. We speculated that the formation of dimers, 
trimers or other non-micellar molecular clusters at these concentrations (3000nM and 
5000nM) could have partially inhibited enzyme degradation which resulted in a 









S11. Cell Culture and In-vitro Studies 
S11.1 Cell culture 
Human breast adenocarcinoma cell line, MCF-7 was kindly provided by Wirtz 
Lab at Johns Hopkins University, and was grown in Dulbecco’s Modified Eagle Medium 
(DMEM, Invitrogen) containing 10% of Fetal Bovine Serum (FBS, Invitrogen) and 1% 
of penicillin and streptomycin (Invitrogen). This breast cancer cells were incubated at 
37
o
C in a humidified incubator with a 5% CO2 atmosphere in all the experiments. 
S11.2 Flow Cytometry 
The time-dependent fluorescence increase on MCF-7 was quantified using flow 
cytometer (FACSCalibur, BD). In brief, MCF-7 cells were seeded onto a 24-well plate at 
density of 1 × 10
5
 cells/well, and allowed to attach overnight. The medium was replaced 
with fresh complete medium containing 5 μM TFB and incubated for 0.5, 1, 1.5, 2, and 
2.5 hours. Then, the cells were washed 1 time with DPBS, and further treated with 
Trypsin to harvest cells from each well. Finally, MCF-7 cells were washed 3 times with 
ice-cold DPBS, and immediately analyzed using flow cytometer at FL1 channel. The 
viable cells were gated according to forward scatter (FSC) vs. side scatter (SSC) profile, 




Figure S11.  A plot of Geometric Mean Intensity versus incubation time shows a linear 
correlation. 
 
S11.3 Confocal Imaging 
The time-dependent fluorescence increase in MCF-7 cells was imaged using a 
confocal laser scanning microscope (CLSM, LSM 510, Zeiss) leaving the pinhole wide 
open. Briefly, MCF-7 cells were seeded onto a collagen (Invitrogen) coated 8-chamber 
glass bottom plate (Lab-Tek) at a density of 3 × 10
4
 cells/well, and allowed to attach 
overnight. The medium was replaced with fresh complete medium containing 5 μM TFB. 
After 0.5 and 1.5 hours incubation, the cells were washed 3 times with DPBS, and fixed 
with 100 μL of 4% paraformaldehyde for 10 min at 4 
o
C. Then, the paraformaldehyde 
was removed and the cells were washed 3 times with DPBS. In the colocalization 
experiment, the cells were seeded and treated in the same manner except 100 nM 
Lysotracker Red (Invitrogen) and 5 μg/mL Hoechst 33342 (Invitrogen) were added to 
stain the lysosome and nucleus, respectively. These two dyes were added 20 min before 
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cell fixation. Finally, 100 μL of Fluomount-G (Southernbiotech) was added, and the 
samples were imaged immediately using CLSM (pinhole sizes were set to obtain optical 
slice at 0.9 μm). The excitation lasers and filter used are listed in Table S2.  
Table S2. Fluorescence parameters used in confocal imaging setting. 
Fluorophore Excitation Wavelength Emission Filter Color Observed 
Hoechst 33342 405nm 420nm-480nm Blue 
5-FAM 488nm 505nm-550nm Green 
Lysotracker Red 543nm 561nm-754nm Red 
 
 
S11.4 Cathepsin-B inhibition by CA-074 Methyl ester (CA-074 Me) 
In order to verify that Cathepsin-B is responsible to the cleavage of –GFLG- 
linker in MCF-7 cells, we carried out a series of experiments with and without the 
addition of CA-074 Me
330
 , a highly selective, irreversible and membrane-permeable 
Cathepsin-B inhibitor that was purchased from Sigma-Aldrich (Saint Louis, MO). MCF-7 
cells were seeded onto a 24-well plate at density of 1 × 10
5
 cells/well, and allowed to 
attach overnight. Before adding TFB molecule, the cells were pre-incubated with 
different concentrations (0µM - 50 µM) of CA-074 Me for 1 hour
331
 in 500µL of DMEM 
medium. 2.08µL of 1.2mM TFB stock solution was added into cell medium to yield a 
final TFB concentration of 5µM. After incubated for 1.5 hours, the cells were treated 
according to protocol in S10.3 for flow-cytometry evaluation. In fluorescence imaging 
study, MCF-7 cells were washed once with HBSS solution and were imaged using 
JENCO BC-366 Inverted Epifluorescent Microscope in 20x magnification. Both 
fluorescence imaging (Fig. S12) and flow-cytometry (Fig. S13) showed significant 
decrease in 5-FAM fluorescence intensity when CA-074 Me was added to inhibit the 
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activity of Cathepsin-B in cells, which suggested that the main enzyme that corresponded 
to the cleavage of –GFLG- linker in TFB is Cathepsin-B.  
 
 
Figure S12. Fluorescence and transmit light images of (a) MCF-7 control that was not treated 
with any TFB and CA-074 Me molecule.  (b)–(e) MCF-7 cells incubated with 5µM TFB and 
different concentrations (0µM, 10µM. 20µM and 50µM) of CA-074 Me (Cathepsin-B inhibitor).  
 
 
Figure S13. Flow-cytometry of MCF-7 cells treated with 5µM of TFB for 1.5 hours showed 
significant decreased in 5-FAM fluorescence intensity when CA-074 Me (CatB inhibitor) was 
added into medium. 
S11.5 Effect of CA-074 Me on Cellular Uptake and Cytotoxicity 
In order to justify that CA-074 Me was solely inhibiting CatB activity instead of 
interrupting cellular uptake pathway. We have synthesized a new molecule C16TF where 
C16 hydrophobic alkyl chain was used to replace BHQ-1 segment in TFB molecule. We 
(a) MCF-7 Control       (b) 0µM CA-074 Me     (c) 10µM CA-074 Me   (d) 20µM CA-074 Me   (e) 50µM CA-074 Me 
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use C16TF where its fluorescence is independent of CatB activity to study the effect of 
CA-074 Me (CatB inhibitor) on cellular uptake. From the flow-cytometry data (Fig. S14), 
we observed similar fluorescence intensity after incubating MCF-7 with 5µM of C16TF in 
the presence or absence of CA-074 Me. This data further support our previous 
observation (Fig. S13) where CA-074 Me inhibited the activity of CatB in MCF-7 cells, 
resulting in lower fluorescence intensity even after internalization of TFB molecules.  
Cytotoxicity of CA-074 Me was evaluated (Fig. S15) by incubating MCF-7 cells with 
different CA-074 Me concentrations (5µM to 50µM) for 4 hours and similar protocol in 
S10.2 was applied. Fig. S15 showed that MCF-7 remained its high viability after treated 
with CA-074 Me which validated the non-toxicity of the CatB inhibitor. 
 
 
Figure S14. Flow-cytometry of MCF-7 cells treated with 5µM of C16TF for 1.5 hours showed 
that CA-074 Me (CatB inhibitor) is not affecting cellular uptake as MCF-7 cells fluoresced at the 




Figure S15. MCF-7 cells were incubated with various concentrations of CA-074 Me (CatB 
inhibitor) to monitor its toxicity to cells. SRB assay results showed almost 100% of cells 
remained viable after treated with 5µM, 10µM, 20µM, and 50µM of CA-074 Me for 4 hours. 
S11.6 Cytotoxicity 
The cytotoxicity of the TFB was evaluated on MCF-7 cells to make sure that the 
cells were healthy in the following experiments. Briefly, MCF-7 cells were seeded onto a 
96-well plate at a density of 5 × 10
3
 cells/well, and allowed to attach overnight. The 
medium was replaced with fresh complete medium (as described in cell culture protocol) 
containing 0, 1, 5, or 10 μM TFB and incubated for 4 hours. Then, the medium was 
changed to fresh complete medium and incubated for another 48 hours, and the cell 
viability was evaluated using Sulforhodamine B (SRB) based method according to the 




Figure S16. Cell viability test reveals that TFB NB at a concentration of 10 µM shows little 
toxicity to cells. 
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Supporting Information for Chapter 3 
Shape- and Charge-Dependent Cellular Internalization of Self-
Assembling Supramolecular Nanobeacons by Cancer Cells 
 
S1 Synthesis and Characterization of Peptide Molecules 
S1.1 Materials 
All Fmoc amino acids were purchased from Advanced Automated Peptide Protein 
Technologies (AAPPTEC, Louisville, KY) and Rink Amide MBHA resin was purchased 
from Novabiochem (San Diego, CA). 5-Carboxyfluorescein (5-FAM) was purchased 
from AnaSpec, Inc. (Fremont, CA) and Black Hole Quencher1 carboxylic acid (BHQ-1-
CO2H) was purchased from Biosearch Technologies, Inc. (Novata, CA). Cathepsin-B 
(bovine spleen) was purchased from EMD Chemicals (San Diego, CA). 
S1.2 Synthesis 
Standard 9-fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis was 
used to synthesize the Sup35 sequence and the enzyme degradable linker on a 0.25 
mmole scale. This procedure was carried out using the Focus XC automated peptide 
synthesizer (AAPPTEC, Louisville, KY). For both SFB-K and SFB-E molecules, 5-
carboxyfluorescein (5-FAM) was manually coupled at the peptide N-terminus (after 
Fmoc removal) with 5-FAM/HBTU/DIEA at a ratio of 4:4:6 relative to the peptide, 
shaking overnight at room temperature. Subsequently, Black Hole Quencher-1 (BHQ-1) 
was coupled to the Lys ε-amine (after Mtt removal) with BHQ-1/HBTU/DIEA at a ratio 
of 1:0.96:1.7 relative to the peptide, shaking overnight at room temperature. Fmoc 
deprotections were performed using a 20% 4-methylpiperidine in DMF solution for 10 
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minutes, repeating once. Mtt deprotections were carried out using a mixture of 




In all cases, reactions were monitored by the ninhydrin test (Anaspec Inc., 
Fremont, CA) for free amines. Completed peptides were cleaved from the solid support 
using a mixture of TFA/TIS/H2O in a ratio of 95:2.5:2.5 for 3 hours. Excess TFA was 
removed by rotary evaporation and cold diethyl ether was added to precipitate the crude 
peptide. Diethyl ether was slowly removed using low vacuum (~700 mbar) and 30 
o
C for 
20 minutes, followed by high vacuum (~100 mbar) and 40 
o
C of rotary evaporation to 
form a thin film of peptide conjugate on the round bottom flask.  






Scheme S4: Synthesis steps of SFB-K 
1.20% 4-methylpiperidine in DMF 
2. 5-FAM, HBTU, DIEA, DMF 
1. 3% TFA, 5% TIS in DCM 





Scheme S5: Synthesis steps of SFB-E 
 
1.20% 4-methylpiperidine in DMF 
2. 5-FAM, HBTU, DIEA, DMF 
1. 3% TFA, 5% TIS in DCM 







DIEA: diisopropylethylamine  Mtt: 4-methyltrityl 
TFA: trifluoroacetic acid   TIS: triisopropylsilane 











The peptides were purified by preparative RP-HPLC using a Varian Polymeric 
Column (PLRP-S, 100 Å, 10 µm, 150 × 25 mm) at 25 
o
C on a Varian ProStar Model 325 
preparative HPLC (Agilent Technologies, Santa Clara, CA) equipped with a fraction 
collector. A water/acetonitrile gradient containing 0.1% v/v TFA or NH4OH was used as 
eluent at a flow rate of 25 mL/min for SFB-K and SFB-E, respectively. The absorbance 
peak was monitored at 534 nm for both SFB-K and SFB-E molecules. The crude 
materials of SFB-K and SFB-E were dissolved in 20 ml of 0.1% aqueous TFA or 
NH4OH, respectively, and each purification run was carried out with a 10 ml injection. 
Collected fractions were analyzed by ESI-MS (LDQ Deca ion-trap mass spectrometer, 
Thermo Finnigan, San Jose, CA) and those containing the desired product were 
lyophilized (FreeZone -105 °C 4.5 L freeze dryer, Labconco, Kansas City, MO) and 
stored at -30 
o
C.  
S1.4 MALDI-ToF Characterization 
High resolution peptide masses were determined by MALDI-ToF mass 
spectrometry, using a BrukerAutoflex III MALDI-ToF instrument (Billerica, MA). 
Samples were prepared by depositing 1 µL of sinapinic acid matrix (10 mg/ml in 0.05% 
TFA in H2O/MeCN (1:1), Sigma-Aldrich, PA) onto the target spot, and allowed to dry 
for 5 minutes. 1 µL of peptide aqueous solution, SFB-K in 0.1% TFA and SFB-E in 0.1% 
NH4OH were deposited on the corresponding spot and quickly mixed with 1 µL of 
sinapinic acid matrix solution. Samples were irradiated with a 355 nm UV laser and 






Table S3: Expected and observed masses of the synthesized molecules 
MALDI-ToF Exact Mass Observed Mass  
SFB-K 2566.182 2567.747 [M+H]+ 
























































































S1.5 Analytical HPLC Characterization 
Analytical reverse-phase HPLC was performed using a Varian polymeric column (PLRP-
S, 100 Å, 10 µm, 150 × 4.6 mm) with 20 µL injection volumes. A water/acetonitrile 
gradient containing 0.1% v/v NH4OH at a flow rate of 1 mL/min was used and samples 







































S2. Controlling Shape of Self-assembled Nanobeacons 
S2.1 SFB-KE nanobeacon  and sample pre-treatment 
Purified and lyophilized SFB-K and SFB-E powders were pre-treated individually 
in HFIP to disrupt existing hydrogen-bonds and oligomers at concentration of 200 μM. 
SFB-KE was prepared by mixing SFB-K and SFB-E in HFIP at 1:1 ratio (i.e. SFB-K 200 
μM 100 μL + SFB-E 200 μM 100 μL). Samples were aliquoted to glass vials with 200 μL 
in each vials and HFIP was removed using rotary evaporation method. The water bath 
temperature was set to 40 
o
C and samples were dried for 10 minutes with 190 rpm 
rotation. 
S2.2 Spherical SFB-K, SFB-E and SFB-KE nanobeacons 
SFB-K, SFB-E and SFB-KE HFIP pre-treated and rotavap dried samples were 
reconstituted in 25 mM of HEPES buffer and stored at 4 
o
C overnight. 
S2.3 Cylindrical SFB-K and SFB-KE nanobeacons 
SFB-K and SFB-KE HFIP pre-treated and rotavap dried samples were 
reconstituted in 25 mM of HEPES buffer and stored at room temperature for more than 3 
days. 
S2.4 Cylindrical SFB-E nanobeacons 
After HFIP treatment, SFB-E formed polydisperse nanostructures such as 
spherical micelles and cylindrical fibers. To obtain monodisperse cylindrical fibers, 
purified and lyophilized SFB-E poweder was directly dissolved in 1xDPBS at 200 μM 






S2.5 Cryo-TEM images 
 
Figure S4. Cryo-TEM images of cylindrical nanobeacons (a) SFB-K, (b) SFB-E and (c) SFB-KE. 
 
S3 Circular Dichroism of Spherical and Cylindrical SFB 
Nanobeacons  
CD spectra were recorded on a JASCO J-710 spectropolarimeter (JASCO, Easton, 
MD) and all three spherical SFB nanobeacons (Figure S4 a,c,e) were found to adopt a 
random coil secondary structure while cylindrical SFB nanobeacons assumed β-sheet 
secondary structure (Figure S4 b,d,f). All samples were prepared as described in section 
S2 and measurements were conducted at room temperature, using 0.1 mm pathlength 
detachable cell. All CD spectra were normalized using the equations below, where θmr is 
the mean molar ellipticity per residue. 
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M : molecular weight (g/dmol) 
c : concentration (g/cm
3
) 
l : path length (cm) 





Figure S5. Circular dichroism of 200 µM spherical and cylindrical SFB-K (a,b), SFB-E (c,d) and 









S4  Cathepsin-B Enzymatic Activation 
CatB enzymatic reaction buffer was prepared in 50 mM sodium acetate buffer 
with 25 mM L-cystein as enzyme activator and 1 mM EDTA was added as enzyme 
stabilizer. The pH of reaction buffer was validated to 5, the optimum pH for enzymatic 
activity. 0.025 Unit of CatB was pre-incubated in reaction buffer for 5 minutes at 37 
o
C to 
activate the enzyme and SFB nanobeacons were added to reaction buffer to yield a final 
concentration of 1 μM and final volume of 100 μL.  All samples were triplicated and the 
experiment was carried out in a 96-well standard opaque plate. 5-FAM molecule was 
excited at 492 nm and emission was collected at 520 nm with 515 nm cut off. Experiment 
data was collected using a Gemini XPS microplate reader (Molecular Devices, 
Sunnyvale, CA) different time points. After 4 hours of cathepsin B incubation, 
fluorescence intensity increased significantly indicating the activation of SFB 
nanobeacons (release of 5-FAM) resulting from cathepsin B degradation on –GFLG- 
linker. 
 
Figure S6. Fluorescence measurement of 1 μM  (a) SFB-K, (b) SFB-E and (c) SFB-KE nanobeacons at 
time 0 hr and 4 hrs after the addition of cathepsin B enzyme (0.025 Unit), showed significant increase in 5-








S5. Stability of nanostructures at 5μM concentration  
 
 
Figure S7. TEM images showed self-assembled nanobeacons (black arrows) maintained its structures 
at 5 μM concentration and 1 hour incubation in 37 
o
C. Spherical (a) SFB-K, (b) SFB-E and (c) SFB-




Figure S8. TEM image of RPMI 1640 cell medium (without SFB nanobeacons) showed globular protein 







S6 Cytotoxicity Evaluation 
Figure S9. SFB nanobeacons were nontoxic to PC3-Flu cells under experimental condition, 1 hour 
incubation at 37 
o
C. Cell viability remained high (>95%) after treated with SFB nanobeacons at (a) 5 μM 
and (b) 10 μM.  
 
Figure S10. Equimolar of sodium azide (NaN3) and 2-deoxy-D-glucose (DDG), energy-dependent 
endocytotic inhibitors are nontoxic to PC3-Flu cells under experimental condition. Cell viability remained 













Supporting Information for Chapter 4 
Enzyme-Specific Doxorubicin Drug Beacon as Drug-Resistant 
Theranostic Molecular Probes 
 
S1. Synthesis, Purification and Characterization of R8DB Drug 
beacon 
S1.1  Materials 
All Fmoc amino acids were purchased from Advanced Automated Peptide Protein 
Technologies (AAPPTEC, Louisville, KY) and Rink Amide MBHA resin was purchased 
from Novabiochem (San Diego, CA). Doxorubicin·HCl was purchased from AvaChem 
Scientific. (San Antonio, TX) and Black Hole Quencher2 carboxylic acid (BHQ-2-CO2H) 
was purchased from Biosearch Technologies, Inc. (Novata, CA). Cathepsin-B (bovine 
spleen) was purchased from EMD Chemicals (San Diego, CA). 
S1.2 Synthesis of BHQ2-R8 and Dox-GLFG 
Standard 9-fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis was 
used to synthesize the octa-arginine sequence (Fmoc-K(Mtt)RRRRRRRR-Rink) and the 
enzyme degradable linker (Fmoc-GFLG-Wang) on a 0.25 mmole scale. These procedures 
were carried out using the Focus XC automated peptide synthesizer (AAPPTEC, 
Louisville, KY). Doxorubicin (Dox) was manually coupled at the peptide C-terminus 
(after peptide cleavage from Wang resins) of Fmoc-GFLG-CO2H and followed by Fmoc 
deprotection, yielding NH2-GFLG-Dox prodrug. After Mtt removal from octa-arginine 
sequence (Fmoc-K(Mtt)RRRRRRRR-Rink), BHQ-2 was manually coupled to the Lys ε-
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amine BHQ-2/HBTU/DIEA at a ratio of 1:0.96:1.7 relative to the peptide, shaking 
overnight at room temperature. Subsequently, Fmoc was removed and synthesized NH2-
K(BHQ-2)RRRRRRRR was cleaved from Rink resins. To convert the N-terminus free 
amine into carboxylic acid form, 10 fold succinic anhydride was reacted with peptide in 
5xPBS solution, shaked overnight at room temperature. In general, all Fmoc 
deprotections were performed using a 20% 4-methylpiperidine in DMF solution for 10 
minutes, repeating once. Mtt deprotections were carried out using a mixture of 
TFA/TIS/DCM with a ratio of 3:5:92 for 5 minutes, and the procedure was repeated 
twice. In all cases, reactions were monitored by the ninhydrin test (Anaspec Inc., 
Fremont, CA) for free amines. All peptides were cleaved from the solid support using a 
mixture of TFA/TIS/H2O in a ratio of 95:2.5:2.5 for 3 hours. Excess TFA was removed 
by rotary evaporation and cold diethyl ether was added to precipitate the crude peptide. 
The precipitated crude peptide and diethyl ether were phase-separated using 
centrifugation technique (6000 rpm for 1 minute) and diethyl ether solution was 
discarded. To remove as much TFA as possible, the washing step was carried out by 
adding 20 mL of diethyl ether was added to crude peptide, shaked well and centrifuged. 
This procedure was repeated 3 times. All centrifuge tubes were tightly sealed with 
parafilm to minimize evaporation of diethyl ether during high-speed centrifugation.  
S1.3 Synthesis of R8DB 
BHQ2-R8 was first dissolved in 500µL of anhydrous DMF (6.8 µmole, 13.6mM). 
Dox-GLFG was also dissolved in 500µL of anhydrous DMF (8.0 µmole, 16mM). Both 
BHQ2-R8 and Dox-GLFG solutions were added to a 10 mL round bottom flask and 
DIEA (26.0 µmole, 4.14 µL) was added in afterward. The mixture was stirred for 10 
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minutes using a magnetic stirrer bar. 5.0 mg of PyAOP coupling reagent (9.6 µmole) was 
added into the solution and left to react for 2 days at room temperature, protected from 
light. Synthesized product was purified using RP-HPLC and characterized by ESI-MS 
and analytical HPLC. The R8DB expected mass is 2881.486 g/mol. Product yield = 1.4 
mg, 0.49 µmole, 7%. 
 
Schemes S1-3 offer details of the synthesis procedures of BHQ2-R8, Dox-GLFG and 
R8DB drug beacon. 
 































The peptides and the drug beacon were purified using preparative RP-HPLC with 
a Varian Polymeric Column (PLRP-S, 100 Å, 10 µm, 150 × 25 mm) at 25 
o
C on a Varian 
ProStar Model 325 preparative HPLC (Agilent Technologies, Santa Clara, CA) equipped 
with a fraction collector. A water/acetonitrile gradient 30%-70% was ran for 90 minutes 
containing 0.1% v/v TFA was used as eluent at a flow rate of 20 mL/min for R8DB drug-
beacon. The absorbance peak was monitored at 580 nm for R8DB drug-beacon. The 
crude materials of R8DB was dissolved in 20 ml of 0.1% aqueous TFA and purification 
run was carried out with a 10 ml injection. Collected fractions were analyzed by ESI-MS 
(LDQ Deca ion-trap mass spectrometer, Thermo Finnigan, San Jose, CA) and those 
containing the desired product were lyophilized (FreeZone -105 °C 4.5 L freeze dryer, 
Labconco, Kansas City, MO) and stored at -30 
o
C.  
S1.5 Electrospray Ionization-Mass Spectra (ESI-MS) 
ESI mass spectra were acquired using a Finnigan LCQ Deca ion-trap mass 
spectrometer equipped with an electrospray ionization source (Thermo Finnigan, San 
Jose, CA). Samples were dissolved in water with 5% of acetonitrle containing 0.1% v/v 
TFA and introduced into the instrument at a rate of 10uL/min using a syringe pump via a 












(a)      (b) 
 
(c) 
   
 
 
Figure S1: ESI-MS spectrum of (a) BHQ2-R8, (b) Dox-GLFG, and (c) R8DB drug-
beacon. In Dox consisting molecule, in-source fragmentation was observed 
corresponding to the partial loss of Dox moiety (indicated by *). Higher laser power 
resulted in the loss of Dox fragments. This phenomenon was also observed in previous 
study.
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. Dox-GLFG exact mass is 917.369, MS (ESI): 1835.7 [2M+H]
+
 , 1857.6 
[2M+Na]
+
  , 940.3[M+Na]
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 , 918.0 [M+H]
+


















S1.6 Analytical HPLC Characterization 
Analytical reverse-phase HPLC was performed using a Varian polymeric column 
(PLRP-S, 100 Å, 10 µm, 150 × 4.6 mm) with 20 µL injection volumes. A 
water/acetonitrile gradient 30%-80% was ran for 30 minutes containing 0.1% v/v TFA at 
a flow rate of 1 mL/min was used and samples were dissolved at 1 mg/ml concentration 
in 0.1% aqueous TFA. 
 
 
Figure S2: Analytical HPLC spectrum of R8DB drug-beacon showed a high purity of 
final product that has an elution time at 12 minutes. 
S2 Cathepsin-B Enzymatic Activation 
S2.1 Fluorescence Kinetics Measurement 
CatB enzymatic reaction buffer was prepared in 50 mM sodium acetate buffer 
with 25 mM L-cystein as enzyme activator and 1 mM EDTA was added as enzyme 
stabilizer. The pH of reaction buffer was validated to 5, the optimum pH for enzymatic 
activity. CatB was pre-incubated in reaction buffer for 5 minutes at 37 
o
C to activate the 
enzyme and R8DB drug-beacon was added to reaction buffer to yield a final 
concentration of 3 μM and final CatB enzyme of 0.005, 0.01 and 0.03 Unit in 100 μL 
reaction volume.  All samples were triplicated and the experiment was carried out in a 
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96-well standard opaque plate. Dox molecule was excited at 490 nm and emission was 
collected at 580 nm with 570 nm cut off. Experiment data was collected using a Gemini 
XPS microplate reader (Molecular Devices, Sunnyvale, CA) different time points. After 2 
hours of CatB incubation, fluorescence intensity increased significantly indicating the 
activation of R8DB drug-beacon (release of Dox) resulting from cathepsin B degradation 
on –GFLG- linker. 
S2.2 Fluorescence Emission Spectra 
Similar to procedure described above, reaction sample consists of 3 μM R8DB 
and 0.05 Unit/100 μL of CatB was prepared in a final volume of 600 μL.  Sample was 
loaded into a Quartz Fluorometer Cell Micro with stopper, 10mm (Starna Cells, Inc.) and 
fluorescence emimssion spectrum was acquired using Fluorolog spectrophotometer from 
Horiba Jobin Yvon (Edison, NJ). Sample was excited with 465 nm and emission 
spectrum was collected from 475 nm-750 nm, with 1 nm wavelength interval.  
     (a)       (b) 
 
Figure S3: Emission spectrum of (a) Dox and (b) R8DB at 3 μM concentration without 
addition of CatB enzyme. Samples were excited with 465nm wavelength and emission 




S2.3 kcat/KM Calculation 
                
         
         
 
 
For Example: Initial Cleavage Rate for 3000nM R8DB with 0.03 U/100 µL CatB is 
1.3936 RFU/min. 
 
                  
   
   
 
         
         
 
    
      
      
     
   
 
 
By using the same method, each initial cleavage rate (V) was calculated and plotted in 
Figure 1c (main text). 
      
 
    
       
     
                     
 
 
CatB Unit information provided by manufacturer: 
 
                     
     
  
 
       
   
 
      
 
           
 
        
  
 
From Michaelis-Menton equation, 
  
    
  
        
 
 
    
 
    
  
    
 




    
 
   
 
 
            
 
    
       
     
             
           
 
        
 
    
          
 
 
    
  
           
     
           
   
 
         
 
 
    
  
 
          
      
 
          
 
 
    
  
       









S3 Confocal Laser Scanning Microscopy 
NCI/ADR-Res were seeded onto 8-well plate with cell density of 3x10
4
 cells/well 
and incubated overnight in 37 
o
C incubator. 9 μL of 100 µM R8DB drug-beacon were 
added to 291 μL of RPMI 1640 cell medium and transferred to each well containing 
NCI/ADR-Res cells. The cells were kept in 37 
o
C for 3 days and then the medium was 
replaced with fresh medium containing drug (R8DB or Dox in corresponding well). The 
cells were incubated for 1 more day. NCI/ADR-Res cells were imaged directly without 
fixing the cells after 4 days of total incubation. The cell nuclei were stained in blue with 
Hoechst 33342 and lysosome compartments were stained with Lysotracker Green for 30 
minutes before the cell imaging. 
S4 Cell Cytotoxicity Assay 
NCI/ADR-Res cells were seeded onto 96-well plate with cell density of 3000 
cells/well and incubated overnight in 37 
o
C incubator. Free Dox and R8DB drug-beacon 
with different concentrations, 0.3 µM, 1 µM and 3 µM were added to corresponding well 
with final volume of 200 µL. All samples were triplicated. After 3 days of incubation in 
37 
o
C, cells were replaced with fresh medium consisting respective drug and incubated 
for another 3 days (total of 6 days) Cell cytotoxicity was evaluated using In Vitro 
Toxicology Assay Kit, SRB based (Sigma-Aldrich, MO) and procedures were carried as 
described in manufacturer’s protocol.  
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Supporting Information for Chapter 5 
Self-Assembling Drug-Peptide Nanofiber Hydrogel with Inherent 
MRI Signal 
 
S1 Synthesis and molecular characterization 
S1.1  Materials  
Fmoc amino acids and Fmoc-Glu(OtBu)-Wang resin were purchased from 
Advanced Automated Peptide Protein Technologies (AAPPTEC, Louisville, KY). 
Pemetrexed (Pem) was purchased from AvaChem Scientific (San Antonio, TX). Lauric 
acid was purchased from Fisher Scientific (Pittsburgh, PA). Hydrochloric acid was 
purchased from EMD Millipore (Billerica, MA), and sodium hydroxide was purchased 
from Fisher Scientific (Fair Lawn, NJ). 
S1.2 Synthesis of FE (C12-FFEE) and PemFE (Pem-FFEE) 
The peptide Fmoc-FFEE was synthesized on a Focus XC automated peptide 
synthesizer (AAPPTEC, Louisville, KY) with the scale of 0.25 mmole by using standard 
Fmoc-solid phase synthesis techniques. Fmoc deprotection was followed using 20% 
4 methylpiperidine in DMF solution for 15 minutes, repeating once. After Fmoc 
deprotection, lauric acid was manually coupled to N-terminus of NH2-FFEE at the ratio 
of Lauric acid/HBTU/DIEA 4:4:6 relative to the peptide, shaking overnight at room 
temperature. The coupling of Pem was performed manually at N-terminus of NH2-FFEE 
Pem/HBTU/DIEA at a ratio of 1.2:1.2:1.8 relative to the peptide, shaking overnight at 
room temperature. In all cases, reactions were monitored by the ninhydrin test (Anaspec 
Inc., Fremont, CA) for free amines. Both FE and PemFE were cleaved from the Wang 
resins using the standard cleavage solution of TFA/TIS/H2O (95:2.5:2.5) for 3 hours. 
Excess TFA was removed by air blow, and the remaining peptide solution was titrated 
with cold diethyl ether to precipitate crude peptide. The precipitated crude peptide and 
diethyl ether were phase-separated using centrifugation technique (5900 rpm for 3 
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minute) and diethyl ether solution was discarded. To remove as much TFA as possible, 
the washing step was carried out by adding 25 mL of diethyl ether to crude peptide, 
vortexed and centrifuged. This procedure was repeated 3 times. All centrifuge tubes were 
tightly sealed with parafilm to minimize evaporation of diethyl ether during high-speed 
centrifugation. After centrifugation, the precipitate was dried under vacuum overnight.  
S1.3  Purification  
The peptides were purified by preparative RP-HPLC with a Varian Polymeric 
Column (PLRP-S, 100 Å, 10 μm, 150 × 25 mm) at 25 
o
C on a Varian ProStar Model 325 
preparative HPLC (Agilent Technologies, Santa Clara, CA) equipped with a fraction 
collector.  
FE peptide was dissolved in 20 ml of 0.1% v/v NH4OH. A water/acetonitrile 
gradient 5%-100% was ran for 30 minutes containing 0.1% v/v  NH4OH was used as 
eluent at a flow rate of 20 mL/min. 
The crude PemFE peptide was initially dissolved in 20 ml of 0.1% v/v NH4OH, 
then diluting with 20 ml of 0.1% v/v TFA. A water/acetonitrile gradient 5%-50% was ran 
for 30 minutes containing 0.1% v/v TFA was used as eluent at a flow rate of 20 mL/min. 
The absorbance peak was monitored at 220 nm. Peptide identity was confirmed 
by ESI-MS (LDQ Deca ion-trap mass spectrometer, Thermo Finnigan, San Jose, CA). 
Collected fractions containing desired products were lyophilized (FreeZone -105 °C 4.5 
L freeze dryer, Labconco, Kansas City, MO) and stored at -30 
o
C.  
S1.4  Electrospray Ionization-Mass Spectra (ESI-MS) 
ESI mass spectra were acquired using a Finnigan LCQ Deca ion-trap mass 
spectrometer equipped with an electrospray ionization source (Thermo Finnigan, San 
Jose, CA). Samples were dissolved in water with 5% of acetonitrle containing 0.1% v/v  
NH4OH and introduced into the instrument at a rate of 10 uL/min using a syringe pump 
via a silica capillary line. The heated capillary temperature was 250 
o
C and the spray 




Figure S1. ESI-MS of (a) PemFE and (b) FE molecules. 
S1.5  Analytical HPLC Characterization  
Analytical RP-HPLC was performed using a Varian polymeric column (PLRP-S, 
100 Å, 10 μm, 150 × 4.6 mm) with 20 μL injection volume. A water/acetonitrile gradient 
5%-100% was ran for 30 minutes containing 0.1% v/v NH4OH at a flow rate of 1 
mL/min.  
Figure S2. Analytical RP-HPLC of (a) PemFE and (b) FE. PemFE isomer resulting in 
the shoulder peak in plot (a). 
S2.  Self-Assembly Characterization Protocols  
S2.1  Transmission electron microscopy (TEM) imaging protocol 
4 mM solutions of FE and PemFE in PBS were prepared by directly dissolving 
lyophilized powders, and allowed to age overnight. A sample for imaging was prepared 
by depositing 5 μL of the solution onto a carbon-coated copper grid (Electron 
 
 169 
Microscopy Services, Hatfield, PA, USA), wicking away the excess solution with a small 
piece of filter paper. Next, 5 μL of a 2 wt % aqueous uranyl acetate solution was 
deposited and the excess solution was carefully removed as above to leave a very thin 
layer. The sample grid was then allowed to dry at room temperature prior to imaging. 
Bright-field TEM imaging was performed on a FEI Tecnai 12 TWIN Transmission 
Electron Microscope operated at an acceleration voltage of 100 kV. TEM images were 
recorded by a 16 bit 2K × 2K FEI Eagle bottom mount camera.  
S2.2  Cryogenic TEM protocol 
To visualize structures without possible artificial effects caused by drying and 
staining, cryo-TEM imaging was performed on the FEI Tecnai 12 TWIN Transmission 
Electron Microscope, operating at 80 kV. FE and PemFE samples were prepared at 4mM 
in PBS, the same concentration as conventional TEM. Prior to sample preparation, all 
TEM grids were treated with plasma air to make the lacey carbon film hydrophilic. The 
Vitrobot with a controlled humidity chamber (FEI) was used to generate a thin film of 
sample on grid. The lacey carbon grid (Electron Microscopy Services, Hatfield, PA) was 
blotted and plunged into liquid ethane pre-cooled by liquid nitrogen. All vitrified samples 
were transferred to a cryo-holder filled with liquid nitrogen to prevent sublimation of 
vitrenous water. The images were recorded by a 16 bit 2K × 2K FEI Eagle bottom mount 
camera. 
S3.  In vitro MRI CEST measurement 
FE, PemFE and free pemetrexed samples were prepared at 10mM in 1xDPBS 
solution. A pH series ranging from 6.0 to 8.5 with an increment of 0.5 was studied, and 
sodium hydroxide or hydrochloric acid solution was used to achieve expected pH. 1M 
solution of sodium hydroxide was prepared by dissolving solid sodium hydroxide in 
deionized water, while 11M hydrochloric acid was diluted with water to 1M hydrochloric 
acid. Samples were triplicated at each pH. After pH adjustment, samples were transferred 




S4. PemFE and FE Hydrogel   
PemFE and FE hydrogel were prepared in the final concentration of 30 mM, 
dissolved in 1xDPBS solution and sonicated for 2 minutes to aid in dissolving 
lyphophilized powder form of respective molecules. Samples were left overnight and 
hydrogel photos were taken by inverting both sample vials. 
S5. Cell Cytotoxicity Assay 
The cytotoxicity of PemFE, FE and free pemetrexed was evaluated on a mouse 
glioma cell line (GL-261). Cells were seeded into 96-well plates at 1500 cells/well in the 
medium DMEM containing 10% FBS and 1% antibiotics solution (penicillin and 
streptomycin), and incubated overnight in 37 
o
C incubator with 5% CO2 (Oasis CO2 
incubator, Caron, Marietta, OH).The three molecules with different concentrations, 0.01 
μM, 0.1 μM, 0.5 μM, 1 μM, 2 μM, 4 μM, 10 μM and 50 μM were added to corresponding 
well with final volume of 200 μL. All samples were triplicated. After 4 days of 
incubation in 37 
o
C, cell cytotoxicity was evaluated using SRB based (Sigma- Aldrich, 
MO) in vitro Toxicology Assay Kit, and procedures were carried as described in 
manufacturer’s protocol. The IC50 (the half maximal inhibitory concentration) values for 
each molecule were obtained by fitting the data using the non-linear regression (curve fit) 
analysis functions with Prism software. 
 
Figure S3. In vitro dose-response relationship study of the PemFE, FE, and free 
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